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Chapter 1 — Introduction 
Background and Significance 
Cancer Survivorship 
Cancer is a major public health problem.  In 2009 there were an estimated 11 million 
cancer survivors in the United States.  Cancer is the leading cause of death among 
women 40 to 79 yr and men 60 to 79 yr.  The most common forms of cancer among men 
are prostate, lung, and colorectal cancer with rates of 158.2, 87.3, and 61.2 diagnoses 
per 100,000 persons, respectively.  The cancer incidence rate among White non-
Hispanic men is 551 diagnoses per 100,000 people compared to African American men 
with 652 diagnoses per 100,000 people.  The most common forms of cancer among 
women are breast, lung, and colorectal with rates of 123.6, 55.4, and 44.8 diagnoses per 
100,000 persons, respectively. White non-Hispanic women are at higher risk for 
developing cancer with 423 diagnoses per 100,000 people compared to African 
American women with 398 diagnoses per 100,000 people.  Cancers of the breast, 
prostate, lung, and colon accounted for an estimated 751,061 new diagnoses (~50% of 
all cancer diagnoses) and 276,000 deaths (~49% of all cancer related deaths) in 2009 in 
the United States.  The lifetime probability of developing cancer for men is 50% (1 in 2) 
and for women 38% (~1 in 3) (1). 
Despite high incidence rates among the general population, advances in 
screening, surgical procedures, and pharmacological interventions have increased the 5 
yr survival rate among all cancers survivors from 50% in 1974 to 66% in 2009 (1).  This 
16% increase equates to ~1.7 million people living with cancer for ≥5 yr after diagnosis 
in 2004 that if diagnosed in 1969 may have not been alive in 1974 (1). 
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While living longer after diagnosis, cancer survivors frequently report physical 
and psychological symptoms associated with cancer or cancer treatment(s) including 
loss of appetite, nausea, difficulty concentrating, fatigue, and depression (2).  Nearly all 
cancer survivors report one or more symptoms affecting their sense of well-being that 
negatively affects physical and social quality of life (QOL) (3). 
Management of symptoms associated with cancer or cancer treatment may have 
limited or no treatment so that clinicians are often left with the option of advising their 
patients that cancer related symptoms are something they have to learn to live with (3).  
However, there is a variety of established interventions to aid in modulating symptom 
severity.  These interventions include individual and family counseling, coping skill 
development, and communication skill development.  These above-mentioned 
interventions broadly focus on improving psychological components of cancer survivor 
well-being rather than physical well-being (4, 5).  However, in the past two decades, 
literature has accumulated that indicates exercise after cancer diagnosis reduces the 
incidence and severity of a variety physiologic and psychosocial symptoms’ frequently 
reported by cancer survivors.  However, the magnitude of symptom improvement among 
exercise interventions in cancer survivors is highly variable among individual exercise 
interventions.  These variations in symptom improvement may due to differences among 
exercise interventions including the type of cancer targeted, stage and type of treatment, 
type of exercise performed, and the primary health outcomes examined (2, 6). 
Exercise Interventions 
The accumulation of literature addressing the effect of exercise on symptom 
management among cancer survivors has spurred various professional organizations to 
develop exercise recommendations tailored for cancer survivors.  These organizations 
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include the American Cancer Society (7), National Comprehensive Cancer Network (3), 
and American College of Sports Medicine (ACSM) (2, 8).  The two sets of ACSM 
exercise guidelines were developed differently; one in the form of guidelines based on 
limited literature-based evidence (8), and the other, an expert panel consensus (2).  A 
noteworthy comment, each exercise recommendation from the American Cancer 
Society, National Comprehensive Cancer Network and the ACSM suggest different 
“Exercise Prescription’s (Ex Rx)” elicit favorable outcomes among cancer survivors.  For 
example, the American Cancer Society and National Comprehensive Cancer Society 
make no recommendation of resistance training among cancer survivors, whereas the 
ACSM suggests resistance training performed two days per week to achieve the health-
benefits associated with exercise. 
The current professional exercise recommendations for cancer survivors (2, 3, 7, 
8) are generic, in that one set of recommendations is used for all cancer survivors.  
However, due to the variety of cancers, their varying pathophysiology, and varying 
treatment regimes, Ex Rx’s may need tailoring specific to the health outcome of interest 
(i.e., reducing depression) for the most efficacious benefits of exercise to be achieved 
(8).  The components of any Ex Rx are frequency (F), intensity (I), time (T), and type (T) 
of exercise performed, labeled the FITT principle of Ex Rx (8).  Frequency refers to how 
often the exercise sessions take place (i.e., 2 d∙wk-1).  Intensity refers to how hard or the 
level of physical exertion is (i.e., low, moderate, or vigorous).  Intensity of exercise can 
be quantified using metabolic equivalent units (METs).  One MET is equal to 3.5 ml∙kg-
1∙min-1, representing oxygen consumption (ml) per kg of body weight per minute while 
sitting quietly.  METs are categorized into light intensity (<3 METs), moderate intensity (3 
to 6 METs), or vigorous intensity (>6 METs).  Time refers to how long each exercise 
session is (i.e., 30 min∙d-1).  Type refers to the modality or kind of activity completed (i.e., 
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cycling, walking, weight training).   
ACSM’s Guidelines for Exercise Testing and Prescription, eighth edition (8) 
provide the most detailed FITT recommendations for cancer survivors.  These 
recommendations focus on a balanced health-fitness program consisting of 
cardiovascular fitness, muscular strength, muscular endurance, and flexibility activities 
(8).  These guidelines suggest moderate-intensity aerobic and resistance exercise, 
complimented with flexibility exercise (Table 1) are appropriate for the general physical 
and mental health of cancer survivors.  However, this FITT Ex Rx is not symptom 
specific and thus, may not be the most effective FITT when attempting to maximize the 
modulation of specific symptoms and health outcomes of cancer survivors. 
Table 1.  American College of Sports Medicine Exercise Guidelines for Cancer Survivors 
(8) 
Modality Frequency Intensity Time Type 
Aerobic 3-5 d∙wk-1 40–60% V02R 3-6 MET 20-60 min∙d
-1 
Walking 
Cycling 
Swimming 
Resistance 2-3 d∙wk-1 40-60% 1RM <3 MET 
1-3 Sets 
8-12 
Repetitions 
Weight Machines 
Flexibility 2-7 d∙wk-1 Tension 10-30 Seconds 4 Repetitions Stretching 
MET: Metabolic equivalent, 1 MET = 3.5 ml·kg-1·min-1. 
V02R:  Maximal Oxygen Consumption Reserve.    
1RM: 1 Repetition Maximum. 
 
The panel of ACSM exercise experts among cancer survivors (2) advised cancer 
survivors to follow the recommendations set forth by the American Cancer Society (7).  
The American Cancer Society guidelines emphasize cancer survivors accumulate ≥150 
min∙wk-1 of aerobic exercise and make no mention of resistance training or flexibility 
exercise (7).  The ACSM expert panel recommended in addition to the American Cancer 
Society Guidelines of 150 min∙wk-1 of aerobic exercise (7), moderate intensity, 
resistance and flexibility exercise be performed to achieve the general health benefits 
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associated with exercise among cancer survivors.   The expert panel concluded exercise 
is safe among cancer survivors during and after completion of primary pharmacological 
treatment (i.e., radiation, chemotherapy).  However, the panel acknowledged there are 
considerable gaps in the dose of exercise most effective in reducing the incidence and 
severity of specific symptoms associated with cancer or cancer treatment.  Similar to the 
ACSM expert consensus statement (2), the National Comprehensive Cancer Network 
and American Cancer Society suggest accumulating 150 min∙wk-1 of aerobic exercise is 
efficacious to achieve the health related benefits of exercise specific to cancer survivors  
(3, 7).  However, these guidelines set forth by the ACSM (2, 8) are a general framework 
that may require adaptation and tailoring as appropriate for the cancer survivor based on 
disease and functional status, and presence of other comorbidities (2). 
Cancer-Related Symptoms and Side Effects 
Cancer-Related Fatigue (CRF) 
CRF is the most frequent symptom experienced by 70-100% of all cancer survivors (9).  
CRF is as a distressing, persistent, subjective sense of physical, emotional, and/or 
cognitive tiredness or exhaustion related to cancer and/or cancer treatment (3).  The 
magnitude of CRF is not proportional to recent activity and may interfere with usual 
functioning and QOL (3).  CRF should not to be confused with general fatigue.  General 
fatigue differs from CRF in general fatigue is proportional to recent activity and is usually 
relieved after rest periods of sleep.  In contrast, the magnitude of CRF does not diminish 
after a rest period of sleep and may persist for weeks or even years (3). 
van den Beuken-van Everdingen et al. (10) surveyed 1,429 cancer patients at 11 
cancer treatment centers.  The primary aims of this study were to: (i) measure the 
prevalence of symptoms related to all types of cancer; (ii) determine the impact 
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symptoms have on QOL; and (iii) inquire whether patients receive treatment for their 
complaints/symptoms.  Patients were diagnosed with a variety of cancer types, most 
commonly breast (24%) followed by colorectal (14%), prostate (13%), and lung (5%) in 
all stages of treatment.  The symptoms “need to rest” and “tiredness” were the most 
commonly reported symptoms when compared to all other symptoms associated with 
any type of cancer (Table 2).  The symptoms “need to rest” and “tiredness” did not 
appear to diminish after completion of curative treatment and affected survivors 
regardless of treatment status.  The symptoms “need to rest” and “tiredness” diminished 
QOL among this sample (β = -0.261, p < .001) (10). 
Table 2.  Most Commonly Reported Symptoms in Cancer Survivors (10) 
Treatment Stage Symptoms 
 “Need to rest” “Tiredness” 
≥ 6 months after curative treatment (n  = 384)* 24% (n = 92) 28% (n = 107) 
≤ 6 months after curative treatment (n = 384)* 36% (n = 138) 36% (n = 138) 
Palliative Therapy (n = 571)** 43% (n = 245) 45% (n = 256) 
*Includes treatments chemotherapy, radiation therapy, hormone therapy, and bone 
marrow transplant procedures.   
**Includes treatments of physical or occupational therapy, psychosocial counseling, and 
hormone therapy. 
  
 Despite the growing literature examining CRF, outcomes have varied 
considerably, ranging from one-fold increases in CRF to two-fold reductions from 
baseline in response to exercise (11).  In addition to the previously discussed literature, 
five meta-analyses examining the role of exercise in the modulation in CRF have 
quantified the high variability in randomized controlled exercise trials examining CRF (6, 
11-14).  Three of these meta-analyses (11, 13, 14) examined CRF moderators or 
variables that may influence the magnitude of CRF reduction in response to exercise.  
Moderators included type of cancer, a CRF driven hypothesis, methodological quality, 
and supervision of exercise sessions.  Breast cancer survivors decreased CRF more 
than non-breast cancer survivors (11, 13, 14).  Exercise interventions with an ‘a priori’ 
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CRF related hypothesis achieved greater reductions in CRF than studies without an a 
priori CRF hypothesis, and studies of lower methodological quality reduced CRF more 
than exercise interventions of higher methodological quality (14).  However, no meta-
analysis has examined the Ex Rx FITT components as they modulate CRF among adult 
cancer survivors.  Further, no meta-analysis has examined any potential interactions 
between the Ex Rx FITT components and clinical characteristics of cancer survivors 
(i.e., the interaction of stage of treatment with intensity of exercise and the subsequent 
modulation on CRF). 
Depression 
Sixteen to 60% of cancer survivors experience depression (15).  Depression among 
cancer survivors may constitute any of the following symptoms: recurrent feeling or 
thought of death, changes in body image, negative self-esteem or societal role or 
lifestyle changes, or concern over money and legal matters (16).  Prior to treatment, 
cancer survivors experiencing less depression had a lower incidence and severity of 
depression at 5 yr follow-up than cancer survivors reporting more depression prior to 
treatment (4).   
The use of physical activity as a non-pharmacological modality to aid in the 
treatment of depression or depression-related symptoms among healthy populations has 
been investigated for more than a century (17).  Meta-analyses of prospective 
intervention studies examining the effects of exercise and depression have supported 
the use of exercise as a non-pharmacological modality to reduce depression among 
apparently healthy populations, with small to moderate sized standardized mean 
reductions (18, 19).  These meta-analyses (18, 19) have examined moderators of 
exercise related reductions in depression including age, length of the exercise 
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intervention, exercise modality, and type of depression questionnaire used.  Lawlor et al. 
(18) meta-analyzed 14 exercise interventions among men and women aged 24 to 88, 
apparently healthy population only diagnosed with clinical depression.  They found 
studies with a shorter exercise intervention length were more efficacious in reducing 
depression than standard care.  Conn et al. (19) meta-analyzed 60 exercise 
interventions among non-cancer survivors, apparently healthy population only diagnosed 
depression, and concluded studies providing low intensity, aerobic exercise reduced 
depression to the greatest extent.  Additional moderators identified by Conn et al. (19) 
included methodological considerations relating to random assignment and control group 
management, with studies of higher methodological rigor reducing depression to a lesser 
extent than studies of poor methodological quality.  Additionally, studies providing a true 
control group reducing depression more than studies providing a placebo, attention 
control (19).  
Despite a large majority of research examining the efficacy of exercise in 
apparently healthy populations, there is emerging observational and interventional 
researching examining exercise and depression among cancer survivors.  Chen et al. 
(20) observed 1,399 women diagnosed with stage 0 to III breast cancer. Concluding 
women with higher exercise levels (≥8.3 MET h∙wk-1) were less likely to have depression 
at 18 months post diagnosis; the multivariate adjusted odds ratio was 0.56 (95% CI 0.35 
to 0.88).  Yet, contrary to observational studies, prospective exercise intervention studies 
exhibit moderate to large amounts of heterogeneity among RCTs with improvements in 
depression ranging from negligible to three-fold improvements relative to baseline (6, 
12).   
Due to the high variability between individual prospective RCTs, two meta-
analyses have examined the standardized mean exercise-related reduction of 
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depression among cancer survivors (6, 12).  Schmitz et al. (6) and Speck et al. (12) 
concluded evidence is suggestive, but not statistically significant effects, of exercise 
providing a small reduction in depression among cancer survivors (standardized mean 
reductions of 0.20 and 0.30, respectively).   Due to small sample sizes of six (6) and 
seven (12) studies, these meta-analyses may have lacked sufficient statistical power to 
detect a significant effect in the exercise-induced reduction of depression.  In addition, 
Speck et al. (12) reported statistically significant heterogeneity of 85% among 
depression outcomes.  Despite the heterogeneity between studies in this meta-analysis, 
neither (6, 12) examined moderators of the exercise related reduction of depression 
among cancer survivors.  Lack of moderator analyses in these studies (6, 12) is a 
research gap in the literature.  There is high variability between individual exercise trials 
with respect to varying Ex Rx characteristics, and clinical cancer survivor characteristics 
making moderator analysis appropriate to perform (6, 12). 
In summary, cancer survivors are clinically heterogeneous with respect to 
demographic characteristics (i.e., gender, age at diagnosis), disease pathophysiology 
(i.e., type of cancer, tumor location, and staging), treatment protocols, and symptoms 
and side effects impairing activities of daily living (2).  Clinical characteristics specific to 
each cancer survivor may influence the efficacy of an exercise intervention on CRF and 
depression outcomes (5, 13, 14).  For example, type of cancer has been shown to be 
predictive of QOL levels, with gastrointestinal and gynecologic cancer survivors 
experiencing lower QOL relative to lung, breast and prostate cancer survivors among 
others (β = -4.490, β=2.202, p<.001, respectively) (10).  Therefore, the purpose of this 
research is to meta-analytically investigate the influence of clinical (i.e., type of 
treatment, tumor location, and staging) and demographic characteristics (i.e., gender, 
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ethnicity, and age) individually, as well as their interactions with Ex Rx FITT 
characteristics on CRF and depression modulation among cancer survivors.  
Meta-Analysis 
Meta-analysis or quantitative reviewing of the literature is the combining of 
numerical results of individual studies to generate a “summary” result.  In the context of 
this research the effect of the Ex Rx FITT characteristics effects on the modulation of 
CRF and depression among cancer survivors.  Another purpose of the study is to 
examine the extent to which clinical characteristics moderate the exercise-induced 
reductions in depression.  Further, we will examine interactions among the Ex Rx FITT 
characteristics and clinical characteristics influencing the efficacy of exercise to reduce 
CRF and depression among adult cancer survivors.  Findings from this analysis may 
provide guidance as to what specific FITT Ex Rx may prove most efficacious for cancer 
survivors suffering from CRF and depression.   
Specific Aims and Hypotheses 
 
The primary aims of this study are: 
Specific Aim 1.  To meta-analyze the literature to determine the efficacy of exercise 
interventions on reductions in CRF and depression among cancer survivors.   
Hypothesis 1.  Cancer survivors engaging in exercise will demonstrate a statistically 
significant reduction in CRF and depression when compared to non-exercising controls. 
Specific Aim 2. To meta-analyze the literature to examine the influence of the Ex Rx 
FITT components on reductions in CRF and depression among cancer survivors. 
Hypothesis 2.  Ex Rx FITT components will modulate the magnitude of the reduction in 
CRF and depression. 
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Specific Aim 3.   To meta-analyze the literature to examine the influence of patient 
clinical characteristics (i.e., cancer type, treatment staging, and age) on reductions in 
CRF and depression among cancer survivors. 
Hypothesis 3. Patient clinical characteristics of cancer survivors will modulate the 
magnitude of the reduction in CRF and depression that result from exercise. 
Specific Aim 4.  To meta-analyze the literature to examine the influence of the 
interactions among Ex Rx FITT components (specific aim 2 & hypothesis 2) and patient 
clinical characteristics (specific aim 3 & hypothesis 3) on reductions in CRF and 
depression among cancer survivors. 
Hypothesis 4.  The interactions among Ex Rx FITT components and patient clinical 
characteristics will modulate the magnitude of the reduction among cancer survivors. 
 
B. Significance 
Cancer is a disease of global impact with an estimated 25 million cancer survivors 
worldwide (21).  Globally, the World Health Organization (WHO) has assembled a panel 
of cancer experts to develop long-term cancer goals and objectives (21).  Specifically the 
WHO has established goals for cancer survivorship.  The specific WHO goals are to 
increase the QOL among those living with cancer, and to provide relief from pain and 
other distressing symptoms among all survivors of cancer.  The long-term goal of the 
WHO is to establish National Cancer Control Programs for holistic cancer guidance in all 
countries, worldwide (21). 
Nationally, the US has developed 10 yr health and disease prevention goals and 
objectives (22).  The two over-arching goals of Healthy People 2010 were to increase 
quality and years of health life, and to eliminate health disparities.  Healthy People 2010 
included a target area specific to cancer, addressing a variety of screening, treatment 
and long-term survivorship goals.  Specific to this research project, goal three, objective 
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15, was to increase the proportion of cancer survivors who are living 5 yr or longer after 
diagnosis to 70%.  Healthy People 2010 failed to reach the target set at 70%, but did 
increase 5 yr survivorship to 64%.  Despite not reaching the objective of 70%, the 
percentage of cancer survivors living ≥5 yr after diagnosis did increase by 45% from 
year 2000.  Increasing 5 yr survivorship among cancer survivors has been a renewed 
objective in Healthy People 2020 (22).  The desired percentage of cancer survivors living 
≥5 yr after diagnosis for Healthy People 2020 is 76%.   
The clinical significance of this research is two-fold.  No study to date has meta-
analyzed exercise intervention FITT Ex Rx characteristics that influence CRF and 
depression among cancer survivors.  This study may provide further support for the use 
of exercise as a non-pharmacological modality for clinicians to recommend to cancer 
survivors with CRF and depression.  This study may also provide quantitative evidence 
for the use of specific Ex Rx FITT recommendations targeted to those patients suffering 
with CRF or depression based on desired health outcome and clinical characteristics. 
In summary, the purpose of this research is to quantitatively summarize the effect 
of exercise on the modulation of CRF and depression among cancer survivors and 
generate hypotheses for future research.  Quantitatively summarizing the literature on 
exercise and cancer survivorship will shape future exercise interventions, and more 
importantly, improve current palliative care practices for those cancer survivors currently 
living with CRF and depression.  
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Chapter 2 — Methods 
We investigated the variability in FITT Ex Rx and the extent to which exercise modulated 
CRF and depression among cancer survivors using meta-analytic techniques.  This 
chapter describes the procedures used for the meta-analysis including the literature 
search, initial screening of studies, full-text review, data extraction, calculation of study 
level effect size, calculation of the pooled effect, tests for heterogeneity, publication bias, 
and meta-regression techniques. 
Literature Search 
Types of participants:  Studies considered for inclusion investigated the use of 
exercise in attempt to modulate CRF or depression levels in adults 18 yr or older.  We 
included both, men and women, all cancer types, stages of cancer, and types of cancer 
treatment.  Subjects were currently receiving treatment, in long-term follow-up, or 
receiving palliative care.   
Types of interventions:  Studies considered for inclusion evaluated and reported the 
effect of exercise on CRF or depression levels in cancer survivors.  Studies compared 
an exercise intervention group to a non-exercise, usual care group, or compared an 
exercise group to an alternative non-physical intervention such as audio therapy or 
aroma therapy.  The exercise intervention occurred in any setting; home, public location, 
or medical center. Exercise interventions may have been conducted in group-format 
(e.g., group exercise classes) or individually (i.e., personal training).  All modalities of 
exercise were considered for inclusion (i.e., aerobic, strength, neuromotor, and flexibility 
exercises).   
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Types of outcome measures:  The primary outcome measures were self-reported CRF 
or depression levels.  To be included, assessment of CRF and depression levels 
occurred at the start of the exercise intervention and at completion, for each group, 
intervention and control, respectively.   
Search methods for identifying relevant studies:  The following databases were 
searched for relevant studies to be included in this meta-analysis; MEDLINE; The 
Cochrane Controlled Trials Register; PsycINFO, Dissertation Abstracts International, 
and OregonPDF in Health and Human Performance.  The CRF systematic search ended 
February 2010, and the depression systematic search ended December 2010.  Citation 
lists of all relevant literature were reviewed for additional studies and journals relating to 
cancer survivors were searched (i.e., Journal of Cancer Survivorship).  There were no 
language restrictions when attempting to locate studies for inclusion.  Searches included 
medical subject headings (MeSH) to conduct the systematic literature search (Figure 1).   
Screening of all studies in the comprehensive literature search were completed 
by reviewing the title and abstract for inclusion criteria.  Reviewers (i.e., JB and SP) were 
not blinded to journal title or author.  The reviewers (JB, SP) screened both title and 
abstract for inclusion in this meta-analysis.  To ensure proper screening, approximately 
10% of all excluded studies were re-screened to validate inclusion/exclusion of 
appropriate literature.   
The inclusion criteria included RCTs that use an exercise intervention compared 
to a usual care, or non-exercising control group with CRF or depression measured as an 
outcome variable.  The intervention took place in adults of any age, caner type, 
treatment stage, or other demographic characteristics.   
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Data Extraction:  After appropriate title and abstract screening, the literature was 
subject to a full-text review.  Studies reviewed were issued a unique identification 
number to ensure organization and quality control.  After full-text review, if studies 
continued to meet the inclusion/exclusion criteria, data were extracted via a 
comprehensive coding form (see Appendix).  Data extracted included information on 
subject demographics (e.g., age, gender, socioeconomic status), study design 
characteristics (i.e., randomization and blinding procedures, length of exercise 
intervention, and location of exercise intervention), and subject cancer characteristics 
(e.g., cancer type, treatment type, and time length since diagnosis).  Characteristics 
regarding the FITT Ex Rx employed were also extracted.  Specifically, how often 
(frequency), how hard (intensity), time (duration) and mode (type) of exercise were 
extracted.  Intensity of exercise was coded in metabolic equivalent units (METs) using 
the compendium of MET intensities (1).  This compendium is valid and widely used in 
physical activity disciplines for coding absolute energy expenditures. 
Data Extraction Agreement:   Kappa statistic and Pearson’s r assessed individual 
coder agreement for categorical variables and continuous variables, respectively. The 
Kappa statistic accounts for the degree of chance occurrence agreement between the 
two coders.  This statistic provides information on the reliability and reproducibility of the 
coders, and accounts for the degree of chance occurrence between coders in addition to 
actual agreement (2).  Superior to simply calculating percent agreement, the Kappa 
statistic ensures quality control in data extraction.   
The guidelines for interpreting the Kappa statistic were <0 = poor, 0.00-0.20 = 
slight, 0.21-0.40 = fair, 0.41-0.60 = moderate, 0.61-0.80 = substantial, and 0.81-1.00 = 
almost perfect agreement (2, 3).  Even in the presence of substantial or almost perfect 
agreement, the Kappa statistic may appear low, ranging from 0.61-1.00, respectively.  
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The guidelines for interpreting Pearson’s r were 0.00-0.49 = low to no agreement, 0.50-
0.79 = moderate or medium agreement, 0.80-1.00, strong, or perfect agreement (2).  
The Kappa statistic was applied to categorical study dimensions and Pearson’s r was 
applied to continuous study dimensions.    
Individual Effect Size Estimates:  Because the majority of randomized controlled trials 
(RCTs) reported continuous measures of CRF and depression, standardized mean 
difference effect sizes were used.  Effect sizes were used to estimate the efficacy of the 
FITT Ex Rx on the modulation of CRF and depression.  The standardized mean 
difference effect size (d) was the mean difference between the treatment and control 
groups divided by the pooled standard deviation (4).  The effect size d has a slight bias 
tending to overestimate the true population mean ( ) when studies have small sample 
sizes.  We removed this bias by applying a correction factor that yields an unbiased 
estimate of ( ) (5).  Applying this correction yielded an error <0.007 and less than 
0.035% when df 10 (6).  This application was applied to all effect sizes prior to 
analysis.  CRF effect sizes are positive when the treatment group reduced their fatigue 
more when compared to the usual care group.  Depression effect sizes are negative 
when the treatment group reduced their depression more when compared to the usual 
care group.  Some studies included more than one treatment group. In this situation, we 
compared each treatment group to the control group, producing two effect size estimates 
from one study (7).   
Mean Effect Size Calculation (Fixed Effects vs. Random Effects) 
Fixed Effects Modeling:  The overall estimate of the effect was calculated using two 
models for each CRF and depression outcomes.  The first, a fixed effect model assumed 
all studies in the meta-analysis were treated as sharing a common effect size.  All 
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factors that could influence the effect size were the same in all studies.  Each individual 
study was assigned a weight. This weight corresponded to the inverse within study 
variance.   
Random Effects Modeling:  In a random-effects model, as with a fixed effects model, 
each study was weighted by the inverse of its variance.  The difference between fixed 
and random effects model was that the weighting not only included within study variance 
(as seen with fixed-effects assumptions) but the between study variance as well, 
denoted 2 (tau-squared).  Random effects modeling provided wider confidence intervals 
around the mean effect size, due to added between study variance.  
Fixed vs. Random Effects Modeling:  The mean effect was the weighted average of 
the means of individual study effects.  We implemented both the fixed and random 
effects models in our analysis to calculate the mean effect.  These values provided an 
estimate on the efficacy of CRF and depression modulation in repose to an exercise 
intervention. 
Publication Bias: We examined both forest and funnel plots for publication bias.  These 
graphical techniques illustrated the variability among sampled studies (forest plot) and 
the expected effect size (funnel plot) by plotting calculated effect size against variance.  
We also assessed publication bias statistically via Begg and Egger publication bias 
methods (6) and the non-parametric “Trim and Fill” method, a non-parametric test for 
asymmetry in the distribution of effect sizes (8).   
Heterogeneity:  The homogeneity in effect sizes measured the differences of similarities 
between studies (9).  Homogeneity (Q) was then calculated to determine if there was 
more variance between studies than would be produced by random sampling alone. Q is 
not a standardized statistic, making its interpretation difficult in a given context.  Q was 
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then transformed to I2, a standardized measure of homogeneity.  I2 values assumed a 
range of 0-100%, indicating homogeneity (0%) or heterogeneity (100%) between studies 
(9).  
Meta-Regression:  Moderators (i.e. covariates) were tested with the FITT Ex Rx and 
clinical characteristics with respect to CRF or depression outcomes, respectively.  
Specific subject demographic characteristics were also examined.  Specific 
characteristics included age, gender, ethnicity, socioeconomic status, education, type of 
cancer, type of treatment, stage of treatment, and time since diagnosis.  Moderators 
listed above were also included within the comprehensive coding form (Appendix A).  
Statistical Computing:  The statistical software package Intercooled Stata version 11.1 
(College Station, Texas) performed all statistical analysis (10).  Although Stata does not 
have built in meta-analytic tools, macros exist for meta-analysis.  These macros were 
freely downloadable and included: meanes, metareg, metaf, metan, metabias, and 
confunnel.  Two-sided statistical significance was set at p < 0.05. 
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Figure 1. Systematic search terms for CRF and Depression among Cancer Survivors. 
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Abstract 
 
Background:  The purpose of this meta-analysis was to explore the efficacy of exercise 
as a non-pharmacological intervention to reduce cancer-related fatigue (CRF) among 
adult cancer survivors.  We also investigated how different components of the exercise 
prescription (Ex Rx), methodological considerations, and subject characteristics 
modulate CRF.  Methods: A systematic search for randomized controlled trials was 
conducted using words related to cancer, exercise, and fatigue.  Results:  In total 44 
studies with 48 interventions qualified, including 3,254 participants of varying cancer 
types, stages of diagnosis, treatments, and exercise interventions.  Cancer survivors in 
exercise interventions reduced their CRF levels to a greater extent than usual care 
controls, d+ = 0.31 (95% confidence interval = 0.22 to 0.40), an effect that appeared to 
generalize across several types of cancer.  CRF levels improved in direct proportion to 
the intensity of resistance exercise (β = 0.60, p = .01), a pattern that was stronger in 
higher quality studies (β = 0.23, p < .05). CRF levels also reduced to a greater extent 
when interventions were theoretically-driven (β = 0.48, p < .001) or cancer survivors 
were older (β = 0.24, p = .04).  Conclusions:  Exercise reduced CRF especially in 
programs that involved moderate intensity, resistance exercise among older cancer 
survivors and that were guided by theory.  Impact:  Our results indicate exercise 
interventions for adult cancer survivors should be multi-dimensional and individualized 
according to health outcome and cancer type.   
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Introduction 
Currently, there are over 11-million cancer survivors in the United States (1).  
The 5-yr survival rate for cancer survivors has steadily increased from 50% in 1974 to 
66% in 2004 (1).  Despite living longer after diagnosis, cancer survivors commonly report 
having one or more cancer-related symptoms that impact their quality of life and 
activities of daily living (2).  One of the most commonly reported symptoms by cancer 
survivors is cancer-related fatigue (CRF) (3).  CRF is a reported side-effect of all types of 
cancer treatment (4) affecting nearly 100% of cancer survivors, and persists for years 
after treatment cessation (5, 6).  Cancer survivors often state CRF is the most 
distressing symptom related to cancer or cancer treatment, more so than pain, nausea, 
and vomiting (2, 7, 8). 
Cancer survivors often are told by medical providers to learn to live with CRF by 
limiting activity, conserving energy expenditure, and relying on others to complete 
activities of daily living (3).  Yet, new evidence is accumulating that indicates cancer 
survivors who engage in exercise experience numerous physical and mental health 
benefits including increased functional capacity (4), improved quality of life (9), and 
diminished depression (10) and anxiety (10).  In addition, meta-analyses (11-14) and 
systematic reviews (15) suggest exercise interventions may be moderately efficacious in 
modulating CRF.   
Despite the promise of exercise in the management of CRF, an exercise 
prescription (Ex Rx) tailored for adult cancer survivors experiencing CRF does not exist 
(3, 4, 16, 17).  The available Ex Rx guidelines for cancer survivors (3, 4, 16, 17) broadly 
focus on the general well-being of cancer survivors, encouraging 150 min/wk of aerobic 
exercise, 2 d/wk of strength training, and flexibility exercise on days when aerobic or 
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resistance exercise is not performed.  An American College of Sports Medicine (ACSM) 
panel of experts in Ex Rx for cancer survivors recently concluded exercise is safe for 
cancer survivors, all cancer survivors should avoid inactivity, and exercise programs 
should be adapted for the individual survivor on the basis of health status, cancer 
treatment type, targeted health outcomes, and disease trajectory (4).  Yet, the panel 
acknowledged research in the area of Ex Rx for cancer survivors is in the developmental 
stage with significant research gaps in the dose of exercise required to ensure cancer 
survivors receive safe and effective Ex Rx for targeted disease end points such as CRF.  
We conducted a quantitative review evaluating the efficacy of exercise as an 
intervention to reduce CRF among adult cancer survivors.  The primary purpose was to 
investigate which Ex Rx characteristics were associated with the greatest reductions in 
CRF.  We also examined whether study methodological considerations and subject 
characteristics combined or interacted with the dose of exercise prescribed to reduce 
CRF further.   
Methods 
Inclusion Criteria 
Included were randomized controlled trials (RCTs) that examined the effects of 
exercise on CRF in adult patients (≥18 years) diagnosed with any type of cancer, stage 
of diagnosis, and type or stage of treatment including those who have completed 
treatment.  Exercise interventions may have occurred in any setting with or without 
supervision.  RCTs may have compared exercise with a usual care group receiving 
either (a) standard, usual care (e.g., no exercise program prescribed and to maintain 
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current activity levels), or (b) non-exercise related information during the intervention 
period.  
[See online appendix I for detailed systematic search information] 
CRF Outcome Measure 
The outcome variable examined was patient-reported CRF (3), which studies 
assessed either separately or as a component of a comprehensive psychological 
questionnaire with a CRF subscale (see: bottom Table 1) (18-23). 
Coding and Reliability 
Two independent raters (JB, SP) coded information related to the study (see 
Table 1).  Intensity of exercise was estimated using metabolic equivalent units (METs), 
where 1 MET = 3.5 ml O2·kg-1·min-1.  Corresponding MET values for a given exercise 
intervention were coded from the Compendium of Physical Activity; these include low 
(<3 METs), moderate (3-≥6 METs), and vigorous (>6 METs) intensity levels (24).  
Methodological quality was assessed via the Physiotherapy Evidence Database scale 
(PEDro).  PEDro guidelines categorize high quality studies from 6-11, fair quality 4-5, 
and poor quality <4. Reliability of the raters was high across dimensions (M Cohen κ (25) 
= 0.78 for categorical variables, M Spearman-Brown reliability (26) = 0.90 for continuous 
variables).  Disagreements between coders were resolved through discussion.   
Study Outcomes and Calculation of Effect Sizes 
Because a majority of RCTs reported continuous measures, effect sizes (d) were 
defined as the standardized mean difference between the exercise and control groups 
divided by the pooled standard deviation, correcting for sample size bias and baseline 
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differences (27).  Multiple effect sizes were calculated from individual studies when they 
included more than one exercise intervention group (e.g., aerobic and resistance training 
groups compared to a control group).  Subsequent sensitivity analyses were conducted 
to confirm the dependence did not influence the mean estimate of the 48 effect sizes 
(28).  Consequently, the 44 included studies provided 48 exercise vs. control group 
comparisons.      
[Insert Figure 1 here] 
Prior to analysis, data were assessed for publication bias using Begg (29) 
(z = 1.01, p = 0.31) and Egger (30) (t = 0.06, p = 0.95) methods, and yielded no 
evidence of publication bias (Figure 3 funnel plot, online).  The trim-and-fill technique 
(31) identified no added or omitted studies were necessary to normalize the effect size 
distribution.  Analyses were conducted in Stata 10.1 with macros for meta-analysis (32).  
The homogeneity statistic, Q, was calculated to determine whether a weighted mean 
effect size (d+) characterized a common effect size.  A significant Q indicated the 
absence of homogeneity (i.e, more variation in effect sizes than sampling error alone 
would predict).  To standardize Q, the I2 statistic and its 95% CI were calculated (33, 34).  
I2 ranges from 0% to 100% with low values suggesting homogeneity and large values 
suggesting heterogeneity.  To explain variability in the effect size estimates, the relation 
between study-level characteristics and the magnitude of the effects, was examined in 
modified least squares regression analysis with the weights equivalent to the variance 
for each study effect size (viz., meta-regression).  Bivariate analysis was conducted 
using fixed-effects assumptions, and the final, multi-moderator analysis was conducted 
using random-effects assumptions.  To reduce multicollinearity in multiple moderator 
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models, all retained continuous moderators were zero-centered, and categorical 
variables were contrast coded.   
[Insert Table 1 and Table 2 here] 
Results 
Potentially relevant reports included 7,245 articles of which 44 (N= 3,254) 
satisfied the selection criteria.  Of the studies identified, 40 provided one CRF effect size 
estimate and four studies provided two estimates, yielding 48 effect sizes among 44 
studies (See Table 1 for descriptive statistics).  Studies providing two effect sizes 
included two independent exercise intervention groups that were compared to one 
standard-care group (46, 49, 55, 69).  Three interventions with multiple intervention 
groups were randomized to aerobic exercise, resistance exercise, or control condition 
(49, 55, 69); whereas the fourth study randomized participants to either supervised 
exercise, unsupervised exercise, or a control condition (46).  The mean methodological 
quality of the 44 included studies was 6.8±1.4 out of 11 (range: 3-10) (Table 2).The 
mean age of cancer survivors was 53.8±10.5 yr, and they averaged 6.7±13.8 months 
post diagnosis.  The majority of cancer survivors were women (86%).  Approximately 
half (46%) of cancer survivors were currently being treated with primary pharmacological 
therapy during the exercise intervention.  For those undergoing therapy, a majority of 
cancer survivors in the sample (75%) were being treated with a combination of 
chemotherapy and radiotherapy, whereas 13% were treated with only chemotherapy, 
6% were treated with only radiation, and 6% were treated with only hormone therapy.   
Twenty-five studies examined exercise interventions exclusively in breast cancer 
survivors (44-55, 57-68), four in prostate cancer survivors (69-72), four in lymphoma (73-
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76), one in leukemia (78), and one in colorectal cancer (77).  The remaining nine studies 
examined exercise interventions in a mixed group of cancer survivors (35-43).  Twenty-
four studies included only aerobic exercise (35, 38, 39, 42-44, 46, 49, 50, 52-59, 61, 65, 
69, 70, 74, 77, 78), six studies included only resistance exercise (49, 55, 63, 68, 69, 71), 
11 studies included a combination of aerobic and resistance exercise (40, 41, 48, 51, 60, 
62, 64, 67, 72, 75, 76), and another six included neuromuscular exercise such as tai-chi, 
or yoga (36, 37, 45, 47, 66, 73) (Table 5 characteristics of included studies, online). 
The average length of the exercise intervention was 11.5±5.2 wk.  Cancer 
survivors exercised 3.5±1.4 d/wk for 48.5±22.8 min/session.  The level of physical 
exertion or average intensity of the aerobic exercise interventions was 5.6±3.0 METs, 
corresponding to moderate intensity exercise (40-60% V02max), and included walking 
(48%), stationary cycle ergometry (30%), a combination of walking and cycling (16%), or 
other modalities of aerobic exercise such as the elliptical trainer or self-selected (6%).  
The average intensity of resistance training was 4.5±2.0 METs, corresponding to 
moderate intensity exercise (60-80% one-repetition maximum, 1-RM), and included 
weight-machines, resistance bands, or free weights (75%).  The remaining studies 
prescribed neuromuscular exercise which commonly included tai-chi or yoga (25%).  
Flexibility exercise was a component of the exercise in 52% of exercise interventions.  
Supervision of exercise sessions was provided in 60% of the exercise interventions.   
Ten studies used a theoretical basis for the exercise intervention (44, 48, 50, 54, 
57-59, 61, 62, 65).  Three interventions (48, 58, 62) followed the Transtheoretical model 
of behavior change (79, 80), two studies (54, 57) followed the model of self-efficacy and 
stages of exercise change (81), three studies (50, 59, 61) followed the Roy adaptation 
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model (82), one study (44) followed the Payne adaptation model (83) and one study (65) 
followed the Levine conservation model (84). 
Overall Efficacy of Exercise Interventions on Modulation of CRF  
Table 3 summarizes weighted mean effect sizes, d+, for all cancer types 
collectively, as well as cancer type individually.  This analysis indicated exercise reduced 
CRF (Table 3 and Figure 2), yet its impact did not attain significance for survivors of 
lymphoma, colorectal, or leukemia cancer, which may have lacked sufficient statistical 
power to detect a difference.  Pooled, the effect sizes for the 48 interventions lacked 
homogeneity, as did the collection of studies addressing breast cancer survivors.  
[Insert Table 3 and Figure 2 here] 
Factors Related to the Magnitude of CRF Modulation 
Bivariate regression analyses examined potential sample, methodological, and 
exercise intervention characteristics. Significant bivariate models were then integrated 
into a combined moderator model to explain unique study variance (Table 4).  When 
integrated the following moderators no longer remained significant: session length (min), 
number of exercise sessions, and treatment with radiation therapy. Four moderators 
impacting CRF modulation in adult cancer survivors remained significant.  Reductions in 
CRF were greater to the extent interventions: (1) adhered to a theoretical model 
(compared to those that did not do so) (β = 0.48, p = <.001); and (2) sampled older 
cancer survivors (β = 0.24, p = .04). Also (3), the greatest reductions in CRF occurred 
with moderate intensity (3-6 METs, 60-80%, 1-RM) resistance exercise (β = 0.60, p = 
.01), particularly for higher quality interventions (interaction β = 0.23, p < .05).  In 
contrast, lower quality interventions were efficacious in reducing CRF at low (<3 METs) 
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and moderate intensity (3-6 METs, 60-80% 1-RM) resistance exercise. Intensity of 
resistance exercise, use of theory, age, and methodological quality together explained 
52% of the variance among exercise interventions for adult cancer survivors.  The 
estimates in Table 4 reveal exercise interventions of moderate intensity (3-6 METs, 60-
80% 1-RM) resistance exercise were successful in reducing CRF, regardless of the use 
of theory in the exercise intervention, age of the cancer survivor, and methodological 
intervention quality.  In contrast, interventions of low intensity resistance (<3 METs, 
<60% 1-RM) exercise showed no significant reduction of CRF when theory was absent 
or in high methodological quality interventions.  Time since diagnosis, aerobic exercise, 
flexibility exercise, or supervision of exercise sessions did not moderate CRF 
modulation.  
[Insert Table 4 here] 
Discussion 
Overall, we found exercise moderately reduced CRF among cancer survivors 
with an effect size of 0.31 (95% CI: 0.22, 0.40), consistent with prior reviews (12, 15).  Of 
note is our new finding that resistance exercise has a positive, quadratic, and exercise 
intensity dose response effect on CRF.  For cancer survivors engaging in moderate 
intensity, resistance exercise (3-6 METs, 60-80% 1-RM) reduced CRF more so than 
those engaging in lower intensity resistance or aerobic exercise of any level of physical 
exertion. Another interesting finding was exercise interventions based upon a theoretical 
model of behavior change or adaptation were more successful in reducing CRF than 
those interventions not based upon such models.  Age was also related to CRF 
reduction, with older cancer survivors reducing CRF to greater levels than younger 
cancer survivors. Lastly, RCTs of stronger methodological quality (i.e., higher PEDro 
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score) reduced CRF less than those of weaker methodological quality.  Our findings 
about exercise interventions based upon theoretical models and of higher 
methodological quality support previous meta-analytic work examining the influence of 
exercise on CRF (11).  They also update the literature with a larger, more diverse 
sample of cancer survivors and types of exercise interventions (11). 
Sub-group analysis relating to cancer type revealed exercise moderately reduced 
CRF, 0.39 (95% CI: 0.27, 0.51) and 0.42 (95% CI: 0.27, 0.57), among breast and 
prostate cancer survivors, respectively.  These findings update and support previous 
meta-analytic reviews advocating the use of exercise as a non-pharmacological 
intervention to reduce CRF among breast and prostate cancer survivors (11, 12).  Sub-
group analysis among leukemia, lymphoma, and colorectal cancer survivors yielded 
non-significant reductions in CRF.   
Four meta-analyses have been conducted examining the effect of exercise on 
CRF (11-14).  Two of these meta-analysis have examined the mean reduction of 
exercise on CRF (13, 14) without accounting for exercise characteristics that may 
moderate the efficacy of exercise on CRF.  The remaining two meta-analyses (11, 12) 
have examined moderators relating to the efficacy of exercise in reducing CRF, 
however, these meta-analyses were comprised of a smaller number of studies (i.e., 17 
(11) and 18 studies (12)), and did not examine specific Ex Rx characteristics included in 
our analysis that may impact CRF modulation.  In our meta-analysis of 48 interventions, 
we found exercise intensity was a significant moderator of CRF among adult cancer 
survivors participating in resistance training programs.  A positive, quadratic pattern 
emerged suggesting moderate intensity resistance exercise interventions were more 
efficacious in diminishing CRF than those of lower intensity or aerobic exercise of any 
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level of intensity. Our finding of the efficacy of resistance exercise reducing CRF was 
somewhat unexpected.  Current exercise guidelines for cancer survivors emphasize the 
importance of participating in aerobic exercise, complimented with resistance and 
flexibility exercises (ACSM Roundtable) (4) and often make no (National Comprehensive 
Cancer Network) (3) or minimal mention (American Cancer Society) (17) of resistance 
exercise.  
A possible mechanism for the effectiveness of resistance exercise in reducing 
CRF among breast and prostate cancer survivors is the attenuation of the progressive 
muscle wasting and disruptions in muscle metabolism that occur with cancer and 
associated treatments (85).  Several hypotheses related to muscle protein synthesis, 
adenosine triphosphate dysregulation, cytokine dysregulation and progressive muscle 
wasting have all been postulated as mechanistic underpinnings of CRF (85, 86).  
Moderate intensity resistance training increases muscle protein synthesis (87), improves 
cytokine response (88), and diminishes the rate of sarcopenia (89) among healthy 
human populations as well as those with compromised muscle function such as those 
with cerebral palsy, and other musculoskeletal disorders (90).  Further, recent evidence 
suggests resistance exercise may provide health benefits such as improved total body 
muscular strength, self-esteem, and vitality in breast and prostate cancer survivors (49, 
72, 91). 
Another interesting finding was older cancer survivors reduced CRF to greater 
levels than younger cancer survivors engaging in any form of exercise.  This finding is of 
particular importance as most cancer survivors are older >65 yr (1), yet most exercise 
interventions have focused on younger cancer survivors (4).  Older cancer survivors are 
frequently challenged with age-related declines in health (i.e., sarcopenia, decreased 
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functional capacity) as well as cancer-related declines in health (e.g., cachexia, body 
composition changes, decreased bone mineral density) (92).  Exercise has been shown 
to elicit favorable health outcomes among older prostate cancer survivors including, 
increased lean body mass and muscle strength, and increase distance walked in 6 
minutes (72). Improving the status of these health parameters (e.g., body-composition, 
muscular strength, and cardiorespiratory fitness) may influence the modulation of CRF 
among other populations of cancer survivors.   
 Exercise interventions that adhered to a theoretical model of behavior 
change(86, 88) or adaptation model (82) achieved larger reductions in CRF than those 
that did not adhere to such models.  Theoretical models provide empirically supported 
frameworks that inform behavior change, and may offer useful information about 
determinants of exercise behavior (93, 94).  An understanding of exercise behavior and 
behavioral determinants among cancer survivors may help clinicians identify specific 
intervention strategies to facilitation adoption and maintenance of an existing exercise 
program in this population.  Theoretical models of adaptation for cancer survivors may 
be efficacious in improving psychological components of mental health (e.g., distress of 
cancer diagnosis) potentially influencing CRF modulation.  Despite the promise of such 
interventions, relatively few of the studies implementing a theoretical framework 
elaborated on the specific role of theory in the exercise intervention.  Therefore, the 
current meta-analysis is limited in its ability to determine the specific underpinnings of 
theory mediating the reduction in CRF.   
This study is subject to several limitations.  Despite our comprehensive review of 
the literature examining CRF in all types of cancer, our search yielded 28 of the 48 
exercise interventions that targeted breast (58%) and prostate cancer (10%) survivors 
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exclusively.  The large number of interventions examining the impact of exercise on CRF 
modulation among breast cancer survivors limits the generalizibility of our findings to 
other types of cancer survivors.  Moreover, we acknowledge that theories of behavior 
change and adaptation models are hypothesized to influence fatigue through different 
mechanisms.  As noted, we combined them into a single category because there were 
relatively few instantiations of theory-led interventions. Despite this limitation, the 
efficacy of the application of either behavior change or adaptation models is promising 
when compared to those not adhering to a pre-specified theory or model.  
Another limitation relates to the major finding of this meta-analysis, that moderate 
intensity resistance exercise may be beneficial in reducing CRF. In particular, no study 
examined resistance exercise interventions >6 METs (>80% 1-RM). It remains unknown 
if more vigorous intensity resistance training would provide greater or lesser reductions 
in CRF.  We did not evaluate adherence to the exercise interventions in this meta-
analysis because most studies did not report this information.  This variable should have 
important moderating effects on CRF modulation.  
In summary, we confirm with the largest meta-analysis of RCTs conducted to 
date that moderate resistance exercise reduces CRF among adult cancer survivors, 
particularly breast and prostate cancer survivors and those of older age.  Cancer 
survivors engaging in moderate-intensity resistance exercise modulated CRF levels 
more than those engaging in low-intensity resistance exercise or low to moderate 
intensity, aerobic exercise.  Further, the most efficacious exercise interventions were 
based upon behavior change and adaptation theory.  Our findings reinforce the notion 
that exercise interventions for adult cancer survivors should be individualized based 
upon the targeted health outcome and possibly cancer type.  In addition, exercise 
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interventions should be multi-dimensional, combining sound exercise as well as 
behavioral science.   
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Figure 1.  Flow diagram of trial identification and selection. 
aFour studies provided two interventions, yielding two effect size calculations 
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Table 1.  Descriptive characteristics of included studies. Means (±SD), except where 
noted 
Descriptive 
Characteristic All Cancer Breast  Prostate  Lymphoma 
Study Characteristics 
Number of studies, k 44 25 4 4 
Year of study 2005±3.5 2004±3.4 2006±2.7 2006±3.4 
Use of theory 27% 22% 0% 0% 
Published in journal 88% 84% 100% 100% 
Subject Characteristics 
Age   53.8±10.5 52.6±4.4 67.9±1.6 49.8±7.4 
Type of treatment     
 Chemotherapy 13% 12% 0% 25% 
 Radiation 6% 8% 0% 0% 
 Hormones 6% 4% 80% 0% 
  Combination 75% 76% 20% 75% 
Stage of treatment     
 Currently treated 46% 33% 80% 100% 
 Previously treated 54% 66% 20% 0% 
Time since diagnosis, mo. 6.7±13.8 6.9±13.1 6.4±14.3 7.3±14.6 
Intervention Characteristics 
Intervention length, wk 11.5±5.2 11.8±4.4 16.0±7.5 12.3±8.3 
Frequency, d/wk 3.5±1.4 3.4±1.1 2.6±0.4 3.3±1.7 
Length, min/session 48.5±22.8 46.6±21.9 60.0±18.4 60.0±21.2 
Aerobic Intensity, METs 5.6±3.0 4.9±2.1 4.9±5.2 5.6±3.5 
Strength Intensity, METs 4.5±2.0 4.5±1.7 2.4±3.2 2.0±1.2 
Flexibility     
 Included 52% 60% 40% 50% 
  Excluded 48% 40% 60% 50% 
CRF scale used     
 FACT 30% 36% 60% 25% 
 Piper fatigue 20% 32% 0% 0% 
 POMS 13% 8% 0% 25% 
 Brief fatigue index 11% 4% 0% 0% 
 Linear analog scale 4% 4% 0% 0% 
 EORTC QOL-C30 11% 0% 20% 25% 
  Other 11% 16% 20% 25% 
FACT, Functional assessment of cancer therapy.  POMS, Profile of mood states.  
EORTC QOL-C30, European organization for research treatment center quality of life-
care 30.  METs, metabolic equivalent units.  Percentages may not sum to 100% due 
to rounding error. 
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Table 2.  Methodological quality of included studies by cancer type         
Citation Total 
Study quality dimension 
1 2 3 4 5 6 7 8 9 10 11 
Thorsen (35) 7     + + - + - - - + + + + 
Brown (36) 7     + + - + - - - + + + + 
Culos-Reed (37) 7     + + - + - - - + + + + 
Dimeo (38) 6     + + - + - - - - + + + 
Dimeo (39) 7     + + - + - - - + + + + 
Adamsen (40) 10     + + + + - + + + + + + 
Mustain (41) 8     + + + + - - - + + + + 
Burnham (42) 7     + + - + - - - + + + + 
Shang (43) 7     + + - + - - - + + + + 
Breast Cancer 
Payne (44) 5     + + - + - - - + + - - 
Galantino (45) 4     + + - - - - - + - - + 
Segal (46) 7     + + - + - - - + + + + 
Carson (47) 7     + + - + - - - + + + + 
Mutrie (48) 10     + + + + - + + + + + + 
Courneya (49) 7     + + - + - - - + + + + 
Mock (50) 7     + + - + - - - + + + + 
McKenzie (51) 8     + + - + - - - + + + + 
Courneya (52) 9     + + - + - + + + + + + 
Drouin (53) 6     + + - + - - - + - + + 
Daley (54) 7     + + - + - - - + + + + 
Yuen (55) 6     + + - + - - - + - + + 
Courneya (56) 8     + + - + - - + + - + + 
Pinto (57) 6     + + - + - - - + - + + 
Pinto (58) 5     + + - - - - - + - + + 
Mock (61) 5     + + - + - - - + - + - 
Heim (60) 6     + + - + - - - + - + + 
Mock (61) 4     + + - + - - - - - + - 
Campbell (62) 6     + + - - - - - + + + + 
Headley (63) 3     + + - - - - - + - - - 
Milne (64) 8     + + + + - - - + + + + 
Caldwell (65) 7     + + - + - - - + + + + 
Vito (66) 7     + + - + - - - + + + + 
Battaglini (67) 8     + + - + - - + + + + + 
Barfoot (68) 7     + + - + - - - + + + + 
Prostate Cancer 
Segal (69) 6     + + - + - - - - + + + 
Windsor (70) 6     + + - + - - - + - + + 
Segal (71) 10     + + + + - + + + + + + 
Galvao (72) 9     + + + + - - + + + + + 
Lymphoma 
Cohen (73) 9     + + + + - - - + + + + 
Courneya (74) 7     + + - + - - - + + + + 
Jarden (75) 7     + + - + - - - + + + + 
Coleman (76) 5     + + - + - - - - + + - 
Colorectal 
Courneya (77) 7     + + - + - - + + + + + 
Leukemia 
Chang (78) 6 + + - + - - - + - + + 
1, eligibility criteria; 2, randomization; 3, concealed allocation; 4, baseline similarity of groups; 5, 
subject blinding; 6, therapist blinding; 7, assessor blinding; 8, outcome measure from >85% of 
subjects; 9, “intention to treat”; 10, between group statistical comparisons; 11, point & variability 
measure. 
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Figure 2.  Forest plot of effect sizes gauging impact of exercise on CRF modulation by 
cancer type with random-effects means.  
NOTE: Weights are from random effects analysis
.
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Table 3.  Weighted mean effect of exercise modulating CRF by type of cancer      
Type of cancer k 
d+ (95%CI)   Homogeneity of d's 
Fixed-effects Random-effects   Q P I2 (95% CI) 
All cancers 44* 0.312 (0.249, 0.375) 0.310 (0.217, 0.403)  93.37 <.001 50% (30, 64) 
Breast 25† 0.388 (0.303, 0.472) 0.391 (0.268, 0.514)  47.16 <.001 42% (10, 63) 
Prostate 4‡ 0.420 (0.270, 0.570) 0.420 (0.270, 0.570)  3.15 .533 0% (0, 96) 
Lymphoma 4 0.199 (-0.025, 0.425) 0.199 (-0.025, 0.425)  2.32 .508 0% (0, 99) 
Colorectal 1 0.057 (-0.469, 0.583) …  … … … 
Leukemia 1 0.779 (-0.141, 1.700) …  … … … 
Weighted mean effect size values (d+) are positive when the exercise intervention was successful in reducing 
CRF compared to standard care.  CRF, cancer-related fatigue.  k, # of studies.  
a44 studies provided a total of 48 effect sizes.  
b25 studies provided a total of 28 effect sizes.   
c4 studies provided a total of 5 effect sizes.   
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Table 4. Intervention characteristics related to CRF reduction for all cancer survivors, showing estimates at light and 
moderate levels of resistance exercise. 
  Estimates of d+ (95% CI)b 
  Intensity of Resistance Exercise 
Study dimension Levela Light (2.0 METs) Moderate (6.0 METs) 
Use of theory Absent -0.034 (-0.207, 0.139) 0.361 (0.141, 0.582) 
 Present 0.354 (0.177, 0.531) 0.749 (0.470, 1.029) 
Age 39 years 0.160 (0.009, 0.311) 0.555 (0.319, 0.791) 
 65 years 0.385 (0.205, 0.564) 0.780 (0.589, 0.971) 
 70 years 0.428 (0.214, 0.643) 0.823 (0.612, 1.035) 
Intervention quality Highest quality (PEDro=10) 0.010 (-0.197, 0.217) 0.594 (0.310, 0.879) 
 Mean quality (PEDro=6.8) 0.289 (0.165, 0.413) 0.684 (0.506, 0.862) 
 Lowest quality (PEDro=3) 0.631 (0.363, 0.900) 0.794 (0.339, 1.249) 
NOTE: Weighted mean effect size values (d+) are positive when the exercise intervention was successful in reducing CRF 
compared to standard care. CRF, cancer-related fatigue.  METs, metabolic equivalent of task. 
aLevels represent values at the extreme observations of each moderator and for other values of interest within that range.  
bd+ and their 95% CI estimates statistically adjust for the presence of the moderators in the mixed-effects model, including the 
linear and quadratic trends for strength intensity, use of theory, age, and intervention quality, held constant at their means 
except for differences in strength intensity and the study dimension in question.   
MET values were provided to demonstrate the emerging patterns among theory, age, and intervention quality with increasing 
resistance exercise intensity, representing light (2.0 MET) and moderate (6.0 MET) intensity.  
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Search strategy 
Searches for studies concluded in February 2010 and utilized electronic 
databases including CINAHL (1981 to 2010), MEDLINE (1949 to 2010), Embase (1973 
to 2010), and Scopus (1996 to 2010).  OregonPDF in Health and Performance (1947 to 
2010), Proquest Dissertations, and Theses (1980 and 2010) were also searched for 
unpublished literature including search words related to; 1) exercise, and 2) cancer and 
3) fatigue.  The following search strategy was utilized for this meta-analysis, using text 
and keyword and MESH terms in each database, with and RCT filter applied: 
The databases PubMed, PsycINFO, CINAHL Plus, SPORTSdiscus, OregonPDF in 
Health and Performance, and ProQuest Theses and Dissertations were searched. We 
searched all databases using  a Boolean search strategy [i.e., (cancer OR neoplas* OR 
tumor OR chemo* OR radiat* OR malign* OR carciniom*) AND (fatigue (fatig*) tired OR 
lethargic OR vitality OR weary OR exhaust* OR energy OR apathy OR lassitude OR 
weakness OR Drained OR sleepy OR sluggish) AND (exercise OR physical activity OR 
aerobic OR cardiovascular OR resistance OR strength OR muscular OR flexibility OR 
walking OR program OR interval OR sport OR fitness OR performance OR movement 
OR stretching OR tai chi OR yoga OR dance OR body OR composition)].  Journals 
focusing on cancer survivorship (Breast Cancer Research and Treatment, Journal of 
Cancer Survivorship, Oncology Nursing Forum, Journal of Pain and Symptom 
Management and the reference lists of included studies were also searched for 
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additional papers and previous meta-analyses(12-14, 95) and systematic reviews (11, 
13-15, 95-99) were searched for additional literature that database searches may have 
missed. 
 
Figure 3.  Funnel plot of effect size estimates.  
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Table 5.  Characteristics of included studies (Online material only) 
 Subject Characteristics  Exercise Characteristics 
Reference N 
Type of 
Cancer Type of Treatment  
Frequency 
(d∙wk-1) Intensity 
Time 
(min∙d-1) Type 
Duration 
(wk) 
CRF 
Measure 
Thorsen (35) 
I=59 Lymphoma 
Breast 
Gynocologic 
Chemotherapy 
  
2 60-70% HRMax 
30 
Walking 
Cyling 
Jogging 
14 EORTC-QOL C30 C=52   
Brown (36) 
I=59 Mixed;             
Not-Specified Radiation 
  
1 N/A 90 Yoga Stretching 8 POMS C=58   
Culos-Reed (37) 
I=20 Majority Breast; 
Others Not 
Specified 
Not Specified 
  
1 N/A 75 Yoga 7 POMS 
C=18   
Dimeo (38) 
I=27 Breast 
Lymphoma 
Lung 
Chemotherapy 
  
7 30-50 RPM 30 Bed-Ergometer 12 POMS C=32   
Dimeo (39) 
I=34 Lung              
Intestinal 
Chemotherapy 
Radiation Surgery  
  
5 80% HRMax 30 
Stationary 
Bike 3 
EORTC-QOL 
C30 C=35   
Adamsen (40) 
I=135 
21 Tumor 
Types Chemotherapy 
  
3 
85-90% 
HRMax             
70-100% 
1RM 
90 
Weights 
Stationary 
Biking 
6 EORTC-QOL C30 C=134 
  
Mustain (41) 
I=19 
Breast Prostate Chemotherapy 
  
3 60-70% HR Reserve 60 
Walking 
Stretch 
Bands 
4 BFI 
C=19   
Burnham (42) 
I=6 Breast                      
Colon 
Chemotherapy 
Surgery 
  
2 40-60% HRMax 
30 Treadmill Biking 10 LAS C=12   
Shang (43) 
I=68 Breast Prostate 
Colon 
Chemotherapy 
Radiaiton 
  
4 50-70% HRMax 
30 Walking 13 PFS 
C=58   
Breast 
Payne (44) 
I=10 
Breast Hormone 
  
4 Moderate Intensity 20 Walking 12 PFS C=10   
Galantino (45) 
I=4 
Breast Chemotherapy Radiation  
  
1 N/A 60 Tai Chi Walking 3 BFI C=4   
Segal (46) 
I=42 
Breast Chemotherapy Radiation Surgery  
  
3 
50-60% V02 
max 
(Supervised) 
30 Walking 26 SF-36 I=40  
5 
50-60% V02 
max (Self-
Directed) C=41 
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Carson (47) 
I=16 
Breast Chemotherapy Surgery 
  
1 N/A 120 Yoga 8 0-9 Scale 
C=20   
Mutrie (48) 
I=101 
Breast Chemotherapy Radiation Surgery  
  
3 50-75% HRmax 45 
Walking 
Cycling 
Aerobics 
12 FACT 
C=102   
Courneya (49) 
I=78 
Breast Chemotherapy 
  
3 
70% V02 max 45 
Cycle-
Ergometer 
Treadmill 
Elliptical 17 FACT-A 
I=82  60-70% 1RM      
2 Sets               
8-12 Reps 
45 Weight-Machines C=82   
Mock (50) 
I=60 
Breast Chemotherapy Radiation Surgery  
  
5 Moderate Intensity 30 Walking 6 PFS C=59   
McKenzie (51) I=7C=7 Breast Chemotherapy Radiation Surgery  3 
Ergometer:     
25W                 
Two Sets  
10 reps 
60 
Arm-
Ergometer 
Weight-
Machines 
8 SF-36 
Courneya (52) 
I=60 
Breast Chemotherapy Radiation 
  
5 60-75 HRmax 30 Walking 10 FACT 
C=48   
Drouin  (53) 
I=13 
Breast Radiation 
  
4 50-70% HRmax 45 Walking 8 PFS 
C=8   
Daley (54) 
I=34 
Breast Chemotherapy Radiation Surgery  
  
3 65-85% HRmax 50 
Not-
Specified 8 PFS C=38   
Yuen (55) 
I=7 
Breast Chemotherapy Radiation Surgery  
 
3 
Moderate 
30 
Walking 
12 PFS I=8  8-12 Reps 
(circuit) 
Weight-
Machines C=7   
Courneya (56) 
I=25 
Breast Chemotherapy Radiation 
  
3 70-75% V02 max 45 
Cycle-
Ergometer 15 FACT-B C=28   
Pinto (57) 
I=9 
Breast Chemotherapy Radiation Surgery  
  
3 60-70% HRmax 50 
Aerobic-
Activities 12 POMS C=12   
Pinto (58) 
I=43 
Breast Chemotherapy Radiation Surgery  
  
5 55-65% HRmax 30 
Walking 
Biking 
Swimming 
12 POMS 
C=43   
Mock (61) 
I=23 
Breast Chemotherapy Radiation Surgery  
  
5 Self-Paced 30 Walking 6 PFS 
C=23   
Heim (60) 
I=32 
Breast 
Chemotherapy 
Radiation Surgery 
Hormones 
  
4 Not Specified 60 
Walking 
Weight-
Machines 
12 FACT 
C=31   
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Mock (61) 
I=9 
Breast Chemotherapy Radiation Surgery  
  
3 Not Specified 30 Walking 16 SAS 
C=5   
Campbell (62) 
I=12 
Breast Chemotherapy Radiation 
  
2 60-75% HRmax 45 
Walking 
Cycling 
Aerobics 
12 FACT-G 
C=10   
Headley (63) 
I=16 
Breast Chemotherapy 
  
3 Moderate Intensity 30 
Not-
Specified 16 FACT-F C=16   
Milne (64) 
I=29 
Breast Chemotherapy Radiation Surgery  
  
3 
Moderate 
Intensity  
2 sets  
10-15 reps 
60 
Cycling 
Rowing 
Weights 
12 FACT-B 
C=29 
  
Caldwell (65) 
I=13 
Breast Chemotherapy Surgery 
  
4 
Light Intensity 
Light 
Resistance 
30 
Walking 
Resistance-
Bands 
12 
SCFC 
(Schwartz 
Cancer) C=12   
Vito (66) 
I=13 
Breast Chemotherapy Radiation 
  
2 N/A 90 Yoga 8 FACT-B 
C=12   
Battaglini (67) 
I=10 
Breast Radiation 
  
2 
Moderate 
Intensity  
3 Sets 
8-12 Reps 
60 
Treadmill 
Cycling 
Weights 
15 PFS 
C=10 
  
Barfoot (68) 
I=10 
Breast Chemotherapy Radiation 
  
2 
40-60% HRmax               
2-3 Sets 
6-12 Reps 
60 
Cycle-
Ergometer 
Weights 
14 PFS 
C=10   
Prostate  
Segal (69) 
I=40 
Prostate Radiation 
  
3 
70-75% V02 
max 
45 
Cycling 
24 FACT-F 
I=40  60-70% 1RM  
2 sets 8-12 
reps 
Weights 
C=41   
Windsor  (70) 
I=33 
Prostate Radiation Hormones 
  
3 60-70% HRmax 30 Walking 8 BFI 
C=33   
Segal (71) 
I=82 
Prostate Hormones 
  
3 2 sets            8-12 reps 60 Weights 12 FACT-F C=73   
Galvao(72) 
I=29 
Prostate Transplant 
  
2 2-4 sets          6-12 reps 45 Weights 12 
EORTC-QOL 
C30 C=29   
Lymphoma 
Cohen (73) 
I=20 
Lymphoma Chemotherapy Radiation 
  
1 N/A 60 Yoga 7 BFI 
C=19   
Courneya (74) 
I=60 
Lymphoma Chemotherapy Radiation 
  
3 75% V02 max 45 
Cycle-
Ergometer 12 FACT-A C=62   
Jarden (75) I=21 Lymphoma Chemotherapy    5 50-75% HRmax 30 Cycle 5 EORTC-QOL 
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C=21 Transplant   C30 
Coleman (76) 
I=14 
Multiple 
Myleoma Chemotherapy 
  
3 N/A 20 
Walking 
Cycling 
Stretch 
Bands 
24 POMS 
C=10 
  
Colorectal 
Courneya (77) 
I=69 
Colorectal Chemotherapy Surgery 
  
4 65-75% HRmax 30 Walking 16 FACT-C C=33   
   
Leukemia 
Chang (78) 
I=11 
Leukemia Chemotherapy 
  
5 Moderate 12 Walking 3 BFI 
C=11  
Wk: week; min: minutes; HRmax : Maximum Heart Rate; HRR: Heart Rate Reserve; V02 max: maximum oxygen consumption; reps: repetition. FACT: Functional Assessment 
of Cancer Therapy; BFI: Brief Fatigue Index; POMS: Profile of Mood States; EORTC-QOL C-30: Quality of Life Compact 30; PFS: Piper Fatigue Scale; LAS/SAS: 
Linear/Symptom Analog Scale.  I = n  for intervention group; C = n  for control group 
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Abstract 
 
Introduction:  The purpose of this meta-analysis was to examine the efficacy of 
exercise in reducing depression among cancer survivors.  In addition, we examined the 
extent to which exercise dose and clinical characteristics of cancer survivors influenced 
the relationship between exercise and reductions in depression.  
Methods:  We conducted a systematic search identifying randomized controlled trials of 
exercise interventions among adult cancer survivors examining depression as an 
outcome.  We calculated effect sizes for each study and performed weighted multiple 
regression moderator analysis. 
Results:  We identified 40 exercise interventions including 2,929 cancer survivors.  
Diverse groups of cancer survivors were examined in seven exercise interventions; 
breast cancer survivors were examined in 26; prostate cancer, leukemia, and lymphoma 
were examined in two; and colorectal cancer in one.  Cancer survivors who completed 
an exercise intervention reduced depression more than controls, d+=-0.13 (95% CI: -
0.26, -0.01).  Aerobic exercise reduced depression in dose response fashion (β=-0.24, 
p=0.03), a relationship evident in higher quality trials.  Depression was reduced most 
when exercise sessions were supervised (β=0.26, p=0.01); and cancer survivors were 
between the ages of 47–62 yr (β=0.27, p=0.01).   
Conclusion:  Exercise training provides a small overall reduction in depression among 
cancer survivors but one that increased in dose-response fashion with aerobic exercise.  
Depression was reduced to the greatest degree among breast cancer survivors, among 
cancer survivors aged between 47–62 yr, or when exercise sessions were supervised.  
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Introduction 
There are over 12 million cancer survivors in the US (1).  Nearly 100% of all 
cancer survivors experience psychological and physical symptoms and side effects 
related to cancer or cancer treatment (2).  Cancer survivors may experience fear of 
death, disease relapse, and body image changes (3) that may contribute to the 
depression experienced by up to 60% of cancer survivors (4) compared to 7% of the 
general US population (5).  Depression associates with chemotherapy noncompliance 
(6, 7) and reduced 5 yr survival rates (8, 9).  Therefore, management of depression 
among cancer survivors is of clinical importance. Exercise is an effective non-
pharmacological therapy to reduce depression among healthy populations (10) with a 
moderate standardized mean reduction when compared to those who do not exercise.  
Exercise provides similar or larger reductions in depression among an array of clinical 
populations including those living with chronic obstructive pulmonary disease (11), 
human immunodeficiency virus (12), and coronary artery disease (13).   
Accumulating evidence suggests exercise training after diagnosis of cancer may 
reduce the symptoms associated with cancer survivorship, improve quality of life and 
reduce cancer-related fatigue (14, 15).  However, the efficacy of exercise to reduce 
depression is inconclusive (2).  Some studies have demonstrated moderate to large 
reductions in depression as the result of exercise programs (16, 17), whereas others 
observe no such reductions (18, 19).  Although a previous meta-analysis (20) quantified 
the heterogeneity of exercise interventions to reduce depression among cancer 
survivors and reported a moderate to large amount of heterogeneity (I2=55%–76%), it 
did not examine moderator variables that could explain the heterogeneity in results.   
Therefore, this meta-analysis examined the efficacy of exercise to reduce 
depression among cancer survivors and attempted to identify exercise prescription and 
clinical factors associated with the greatest reductions in depression. Identification of 
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characteristics moderating the magnitude of reduction in depression may aid clinicians in 
prescribing tailored exercise interventions to better manage depression among cancer 
survivors.   
Methods 
Inclusion Criteria 
Studies were included if they: (1) utilized a randomized controlled design 
comparing an exercise intervention with a control group (i.e., no exercise program 
prescribed and instructions to maintain current activity levels or no exercise related 
information); (2) reported  depression outcomes; and (3) targeted adults diagnosed with 
any type of cancer, regardless of stage of diagnosis or type or stage of treatment. 
Exercise interventions occurring in any setting, with or without supervision, were eligible.  
Systematic Search [See supplementary material for systematic search strategy] 
Coding and Reliability 
 Four independent, trained raters extracted information related to the study with 
high inter-rater reliability, mean Cohen’s =0.90, for categorical variables, and mean 
intra-class correlation r=0.94 for continuous variables.  Absolute intensity of exercise 
was coded using metabolic equivalent units (METs), where 1 MET represents sitting 
quietly (3.5 ml O2∙kg-1∙min-1) and <3 METs, 3 to <6 METs, and ≥6 METs represent low, 
moderate, and vigorous intensity exercise, respectively (21).  We calculated the weekly 
volume of aerobic exercise as the product of minutes of daily exercise and frequency of 
exercise sessions per week (min∙wk-1).  The Physiotherapy Evidence Database scale 
(PEDro) assessed methodological quality of the trials in terms of internal validity and 
statistical reporting (22).  
Study Outcome and Effect Size Calculation 
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Assessment of depression levels among cancer survivors was a continuous 
outcome variable assessed as a component of a comprehensive psychological 
questionnaire with a depression subscale (23) or a questionnaire solely assessing 
depression levels (24-27) (Table 1). In order to standardize these differences across 
studies, the standardized mean difference effect size (d) was calculated to determine the 
difference in depression at follow-up between the exercise and control groups, correcting 
for small sample size bias and baseline depression levels (28, 29).  For two group 
comparisons, d denotes the difference between the mean depression values of the 
control and exercise groups, divided by the pooled standard deviation (30).  When more 
than one exercise group was provided (e.g., aerobic exercise and resistance exercise) 
we calculated multiple effect sizes.  Subsequent sensitivity analysis examined the 
dependence between these effect sizes to confirm the weighted mean effect size of all 
exercise trials (d+) was not influenced by an individual effect size (31).  A negative d 
value indicated the exercise was efficacious in reducing depression compared to the 
control group.   
Stata 11.1 (StataCorp, College Station, TX) with macros developed for meta-
analysis (32) performed all statistical analyses.  Prior to analysis, Begg’s test (33) 
(z=-1.67, p=0.10), Egger’s test (34) (t=-0.12, p=0.90), and the trim-and-fill method (35) 
identified no asymmetries in the effect size distribution suggestive of publication bias.  
Potential heterogeneity or between-study variance was calculated as Q and I2 (and 95% 
CI) (36, 37).  I2 ranges from 0% to 100% with low values suggesting homogeneity and 
large values signifying heterogeneity.  To explain variance in the effect size estimates—
the relation between study level characteristics and the magnitude of effect size—a 
modified, weighted least squares regression was used with weights equal to the inverse 
variance of each exercise intervention effect size (viz., meta-regression).  All statistical 
models pursued fixed effects assumptions. Statistically significant bivariate regression 
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analyses were integrated into a multi-moderator fixed effects regression to determine 
which variables could be eliminated and which explain unique between study variance.  
To reduce multicollinearity in multiple meta-regression models, all continuous variables 
were zero centered, and categorical variables were contrast coded (-1/+1).  Two-sided 
statistical significance was p<0.05.  
Results 
Methodological Characteristics 
Qualifying were 37 relevant randomized controlled exercise interventions (16-19, 
38-70) (N=2,929) with a total of 40 comparisons (k=40) of exercise versus control 
conditions (Figure 1; Supplementary material describes each trial).  Thirty-four studies 
provided one effect size, and three provided two effect sizes (19, 40, 48).  The mean 
publication year of the exercise interventions was 2006±4.2.  A majority of studies (70%) 
were conducted in North America.  The mean PEDro score of the exercise interventions 
was 7.0±1.0 indicating high quality (22).  Implementation of a theory of behavior change 
occurred in 20% of the exercise interventions (Table 1).  Questionnaires assessing 
depression included the Center for Epidemiologic Studies-Depression (25) (40%), Profile 
of Mood States (23) (23%), Beck Depression Inventory (24) (18%), Hospital Anxiety and 
Depression Scale (26) (12%), and Symptom Assessment Scale (27) (7%). 
[Insert Table 1 & Figure 1 here] 
Cancer Survivor Characteristics 
Cancer survivors participating in the exercise trials averaged 51.3±6.5 yr (range: 
39–70).  The majority of cancer survivors participating in the exercise interventions were 
white, non-Hispanic (n=2,255; 77%) women (n=2,548; 87%).  Time since cancer 
diagnosis was 25.3±19.6 months (range: 2.8–73.0).  Exercise interventions were more 
common during curative therapy with 29 of the 40 exercise interventions (73%) occurring 
during treatment (i.e., chemotherapy or radiation treatment).  Diverse groups of cancer 
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survivors were examined in six exercise interventions (38-43), while breast cancer 
survivors were examined in 24 (16, 19, 44-65); prostate cancer (18, 66), leukemia (68, 
69), and lymphoma (17, 70) in two; and colorectal cancer survivors in one (67).    
Exercise Intervention Characteristics  
The mean length of the 40 exercise interventions was 13.2±11.7 wk with a 
session frequency of 3.0±2.5 d∙wk-1 for 49.1±27.1 min∙session-1.  Average weekly 
volume of all exercise was 129.4±64.9 min∙wk-1.  Exercise modalities included walking 
(k=16; 40%), stationary cycling (k=5; 13%), weight machines (k=2; 5%), resistance 
bands (k=3; 8%), and yoga (k=8; 20%).  In addition, flexibility exercises were prescribed 
in 50% of the exercise interventions.  The absolute intensity of exercise was 3.9±1.3 
METs indicating they were of low (i.e., <3 METs) to moderate (i.e., >3 to <6 METs) 
intensity.  A majority of exercise interventions (60%) were supervised.   
The Influence of Exercise on Depression 
Exercise provided a small overall reduction in depression compared to standard 
care among all types of cancer [d=-0.13 (95% CI: -0.26, -0.01)].  Subgroup analysis by 
cancer type revealed significant reductions in depression among breast cancer survivors 
[d=-0.17 (95% CI: -0.32, -0.02)], but no significant difference in depression among 
prostate, leukemia, lymphoma, and colorectal cancer survivors (Table 2).  Collectively, 
the 40 effect sizes of the exercise interventions lacked homogeneity [I2=55% (95% CI: 
35–68), p<0.001], as did the analysis restricted to breast cancer survivors [I2=59% (95% 
CI: 37‒73), p<0.001; Table 2].   
[Insert Table 2 here] 
Moderators of the Influence of Exercise on Depression 
Three moderators explained unique variance relating to the efficacy of exercise 
to reduce depression when entered in a multiple regression model.  Weekly volume of 
aerobic exercise reduced depression in dose response fashion (β=-0.24, p=0.03), a 
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pattern that was more evident in higher quality trials.  Depression was reduced most 
when exercise sessions were supervised (β=0.26, p=0.01); and cancer survivors were 
between 47–62 yr [(β=0.27, p=0.01); Table 3]. The following bivariate moderators 
ceased being statistically significant in the face of the former variables: (1) theory; (2) 
proportion of cancer survivors being non-Hispanic, white race; and (3) months since 
cancer diagnosis (Table 5, supplementary).  
[Insert Table 3 here] 
Discussion 
This review found that exercise provided a small overall reduction in depression 
among cancer survivors, d=-0.13 (95% CI: -0.26, -0.01), but the amount of change 
varied widely across studies. We also attempted to elucidate the exercise dose and 
clinical characteristics modulating the overall reduction of depression among cancer 
survivors.  The new and intriguing findings from these moderator analyses were 
depression reductions were influenced by age, supervision of exercise, and weekly 
volume of aerobic exercise. The largest reductions appeared among cancer survivors 
between 47–62 yr, when exercise was supervised, or as weekly volume of aerobic 
exercise increased. These trends retained significance in a model that included all 
factors simultaneously, suggesting each term has a unique impact in influencing 
depression levels.  
 Our analysis revealed exercise reduced depression among breast cancer 
survivors, d=-0.17 (95% CI: -0.32, -0.02), a pattern that confirms previous reports in the 
literature (71).  We observed non-significant reductions in depression among prostate, 
colorectal, leukemia, and lymphoma survivors, but the lack of statistical significance 
among these types may be due in part to the small numbers of included studies and 
subsequent lowered statistical power to detect differences.   
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Depression reduction occurred in dose response fashion with aerobic exercise 
such that as weekly minutes of aerobic exercise increased so did reductions in 
depression, a finding observed in higher quality trials (Table 3). These trends are 
consistent with experimental evidence suggesting exercise reduces depression in dose 
response fashion among otherwise healthy populations (72).  Consistent with our 
findings, the American College of Sports Medicine consensus statement in exercise and 
cancer survivorship suggests all cancer survivors strive to achieve a large volume of 
aerobic exercise of ≥150 min∙wk-1 to maximize the health benefits (2).  However, the 
clinical translation of advocating larger doses of weekly aerobic exercise may be an 
unrealistic initial exercise prescription for some cancer survivors for many reasons (e.g., 
previous sedentary behavior, constraints of the disease process itself, other comorbities) 
as well as more traditional barriers to exercise such as lack of time (73, 74).  
Accumulating large volumes of aerobic exercise should be progressive, increasing 
duration and frequency of exercise over weeks or months of exercise training as the 
course of the disease process allows and fitness increases (73, 75).   
We found supervised exercise reduced depression more so than unsupervised 
exercise; consistent with improvements in quality of life (14) and fatigue reduction (76) 
among cancer survivors, and reducing depression among apparently healthy 
populations (77).  Supervised exercise training is preferred over unsupervised exercise 
by breast and colon cancer survivors (78, 79), and provides opportunity to receive 
positive feedback and support, increasing compliance and associated mental and 
physical health benefits (80). 
We found cancer survivors between the ages of 47–62 yr reduced depression 
more than <47 and >62 yr, respectively.  The quadratic shape was unexpected as 
previous reports suggest a negative correlation between depression and age among 
cancer survivors (81, 82).  Therefore, we hypothesized it would be younger cancer 
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survivors experiencing the greatest reductions in depression occurring in linear fashion.  
It is unclear why cancer survivors <47 yr did not experience exercise-induced reductions 
in depression.  It is plausible the average weekly aerobic exercise volume performed 
(~130 min·wk-1) was not a large enough dose of exercise to reduce depression among 
cancer survivors <47 yr.  Functional capacity (i.e., V02peak) and age are negatively 
correlated (83).  Thus, reducing depression among cancer survivors <47 yr may require 
a larger volume of aerobic exercise to elicit reductions in depression.  Conversely, the 
lack of detecting a significant reduction in depression among cancer survivors >62 yr 
may be due in part to a floor effect (10).  That is, older cancer experience less 
depression at baseline, and show smaller exercise-induced improvements in depression 
compared to those who are younger (84).     
The findings from this meta-analysis provide additional insight to the physiology 
of depression.  The therapeutic efficacy of monoamine oxidase inhibitors and tricyclic 
anti-depressant medications support the hypothesis of monoamine dysregulation as a 
mechanistic underpinning of depression (85).  Anti-depressants act to increase 
circulating monoamines (86) and similar increases occur in response to acute and 
chronic aerobic exercise (87).  Acute aerobic exercise increases noradrenaline, 
adrenaline, and serotonin above pre exercise levels (87, 88).  Chronic aerobic exercise 
training increases noradrenaline, adrenaline, and serotonin levels above the levels 
elicited by an acute bout of aerobic exercise (87, 89).  The higher concentrations of 
monoamines elicited in response to chronic aerobic exercise training support the use of 
chronic aerobic exercise training to reduce and manage depression (77).  This supports 
our findings that accumulating larger weekly volumes of repeated bouts of aerobic 
exercise reduce depression in dose response fashion among cancer survivors.  
However, the monoamine hypothesis is one hypothesis of the etiology of depression.  
Continued research should investigate the complex physiology of depression and 
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exercise.  In particular, identification of biomarker responses occurring with varying 
doses of aerobic exercise and their subsequent influence on depression.    
Limitations 
Despite our intention to include all types of cancer of any race, 26 of the 40 effect 
sizes (65%) targeted white, non-Hispanic, breast cancer survivors exclusively which has 
been a limitation of previous meta-analyses examining a variety of health-related 
outcomes among cancer survivors (14, 15, 20).  The skewed number of exercise 
interventions among breast cancer survivors limits the generalizability of our findings to 
other types of cancer.  This limitation should provide an impetus for researchers to 
continue investigating the effects of exercise among other cancer types. 
Despite an overall rating of high methodological quality (7.0±1.0 of 11), we did 
note some consistent methodological weaknesses throughout the literature, such as 
inclusion of small sample sizes, inconsistent criterion with respect to study entry 
eligibility and baseline depression levels, and not following intent-to-treat analytic 
strategies.   
Conclusion 
In closing, we confirmed that exercise provides a small reduction in depression 
among cancer survivors, particularly among breast cancer survivors.  Depression 
reduction occurred in dose response fashion with aerobic exercise.  Larger reductions in 
depression also occurred with supervised exercise, and among cancer survivors 47–62 
yr.  Cancer survivors should strive to avoid inactivity; discuss the safety and feasibility of 
exercising with their medical care provider to optimize physical and psychological 
symptom management and improvement; and eventually aim to achieve larger weekly 
volumes of aerobic exercise of aerobic exercise if possible (2). 
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Table 1.  Descriptive characteristics of included studies, subjects and exercise interventions by type of cancer (means ± SD, k 
or % where noted) 
Descriptive Statistic All Cancer Breast Prostate Leukemia Lymphoma 
 Study Characteristics 
Number of studies, k 40a 26b 2 2 2 
Year of study 2006±4.2 2006±3.9 2008±2.1  2008±0.7 2006±3.5 
Published in journal, k 34 21 2 2 2 
PEDro quality 7.0±1.0 6.7±1.1 7.0±0.0 7.5±0.7 7.5±0.7 
 Subject Characteristics 
Total n (% total n) 2929 (100) 1796 (61) 121 (4) 66 (2) 161 (6) 
Gender, n of women (% 
total n) 
2548 (87) 1796 (100) 121 (0) 22 (33) 61 (38) 
Ethnicity, n (% total n)  
  White, non-Hispanic 2255 (77) 1437 (80) – – – 
  African-American 498 (17) 296 (16) – – – 
  Hispanic 88 (3) 54 (3) – – – 
  Asian 59 (2) 18 (1) – – – 
Age, yr 51.3±6.5 50.9±4.7 68.5±1.2 45.2±8.6 52.1±1.5 
Stage of treatment, k  
  Currently treated 29 17 2 2 2 
  Previously treated 11 9 0 0 0 
Time since diagnosis, mo 25.3±19.6 26.9±21.3 – – 29.2±8.0 
 Exercise Intervention Characteristics 
Intervention length, wk 13.2±11.7 15.5±14.2 12.0±5.6 4.0±1.4 9.5±3.5 
Length, min∙session-1 49.1±27.1 54.7±27.5 65.0±35.4 36.0±33.9 61.2±40.6 
Frequency, session∙wk-1 3.0±2.5 2.8±1.3 2.0±1.4 5.0±0.0 2.0±1.4 
Exercise volume, min∙wk-1 123.9±52.2 135.2±25.1 105.0±21.2 180.0±169.7 97.5±0.0 
Aerobic intensity, MET 4.8±1.1 4.7±0.9 4.4±0.8 5.4±2.3 7.0±0.0 
Strength intensity, MET 2.9±0.5 2.9±0.6 3.0±0.0 3.0±0.0 2.5±0.0 
Neuromuscular, MET 2.5±0.0 2.5±0.0 – – 2.5±0.0 
Flexibility, k   
 Included 20 13 2 1 1 
 Excluded 20 13 0 1 1 
Supervision, k  
 Supervised 24 19 2 2 2 
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 Unsupervised 16 7 – – – 
Use of theory, k  
  None 32 21 2 2 1 
  Psychological  8 5 0 0 1 
Depression Scale used, k  
  CES-D 16 9 1 – 2 
  POMS 9 7 – 1 – 
  BDI 7 6 1 – – 
  HADS 5 2 – 1 – 
  SAS 3 2 – – – 
NOTE:  Percentages may not sum to 100% due to rounding error.   
CES-D, Center for Epidemiologic Studies Depression scale; POMS, Profile Of Mood States; BDI, Beck Depression Inventory; 
HADS, Hospital Anxiety and Depression Scale; SAS, Symptom Assessment Scale. 
k, number of studies included. 
MET, metabolic equivalent, 1MET = 3.5 ml O2∙kg∙min-1. 
a 37 studies provided 40 total effect size estimates 
b 24 studies provided 26 total effect size estimates. 
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Table 2. Weighted mean effect of exercise modulating depression by type of cancer 
Type of Cancer k 
d+ (95% CI)  Homogeneity of ds 
Fixed-Effects Random-Effects Q I2 (95% CI) P 
All Cancer 40a -0.13 (-0.21, -0.06) -0.13 (-0.26, -0.01)  86.13 55% (35, 68) <0.001 
Breast 26b -0.19 (-0.28, -0.09) -0.17 (-0.32, -0.02)  60.79 59% (37, 73) <0.001 
Prostate 2 -0.20 (-0.66, 0.25) -0.20 (-0.82, 0.40)  0.00   0% (0, 100)   0.948 
Leukemia 2 -0.22 (-0.73, 0.30) -0.24 (-0.89, 0.40)  0.94   0% (0, 100)   0.332 
Lymphoma 2 -0.35 (-0.67, -0.03) -0.30 (-0.89, 0.29)  0.64   0% (0, 100)   0.424 
Colorectal 1 -0.08 (-0.52, 0.35) –  – – – 
NOTE:  Weighted mean effect size values (d+) are negative when the exercise intervention was successful in reducing  
depression compare to standard care.   
k, number of studies. 
a37 studies provided 40 total effect size estimates. 
b24 studies provided 26 total effect size estimates. 
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Table 3.  Multi-moderator intervention characteristics related to depression change for all cancer survivors 
Study dimension and levela  Adjustedb d+ (95% CI) βc P 
Accumulated weekly 
volume of aerobic 
exercise, min∙wk1  
PEDro methodological 
score  
 
 
PEDro=5 (lower 
quality) 
 
 
  90 min∙wk-1 -0.29 (-0.54, 0.04) -0.24d 0.03 
120 min∙wk-1 -0.19 (-0.40, 0.02) 
150 min∙wk-1 -0.09 (-0.34, 0.14) 
180 min∙wk-1 0.00 (-0.34, 0.34) 
PEDro=10 (higher 
quality) 
 
 
  90 min∙wk-1 -0.07 (-0.42, 0.27)   
120 min∙wk-1 -0.28 (-0.54, -0.02)   
150 min∙wk-1 -0.49 (-0.77, -0.23)   
180 min∙wk-1 -0.71 (-1.09, -0.33)   
Supervision of exercise  Unsupervised -0.13 (-0.23, -0.04) 0.26 0.01 
  Supervised -0.36 (-0.55, -0.18)   
Age,e y (Quadratic) 
 
 40 0.16 (-0.08, 0.41) 0.27 0.01 
 50 -0.20 (-0.30, -0.10)   
 60 -0.25 (-0.42, -0.08) 
 70 0.01 (-0.47, 0.56) 
NOTE:  Weighted mean effect size values (d+) are negative when the exercise intervention 
reduced depression compared to the control group.  The regression equation is -0.2289–
0.0164(age, y)+0.0016(age2, y)+0.1117(supervised)–0.0993(PEDro)–0.0007(Min week aerobic 
exercise)–0.0021(PEDro×Min week aerobic exercise), where each continuous variable was zero-
centered, and categorical variables were contrast coded (+1 vs -1). 
aLevels represent values of interest of each moderator. 
bd+ and their 95% CI estimates statistically adjust for the presence of the rest of the moderators in the 
fixed-effects model, including weekly minutes of exercise  PEDro interaction and their independent 
linear terms, supervision of exercise, quadratic and linear trends for age, held constant at their means 
except for the study dimension in question. 
cβ values are standardized. 
dβ for interaction.  Independent β: weekly aerobic volume, β = -0.09; PEDro methodological score, β = -0.28. 
eContinuous quadratic trend including linear component.
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Figure 1.  Flow diagram of exercise intervention identification and selection 
 
a Three studies provided two interventions, yielding two effect size calculations 
RCT, Randomized controlled trial 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relevant Abstracts 
  (k=14702) 
Potentially Relevant Sources                               
(k=108) 
Potentially Appropriate RCTs       
(k=71) 
RCTs Included in Final 
Analysis    (k=37) 
Abstracts Excluded (k=14594) 
1. Duplicates (k=4407) 
2. No cancer survivors (k=4632) 
2. No exercise (k=3859) 
4. Targeted children (k=1696) 
Studies Excluded (k=37) 
1. Not an RCT (k=18) 
2. No use of exercise (k=11) 
3. No intervention (k=8)  
  RCTs Excluded (k=34) 
1. Matching of groups (k=28) 
2. No use of exercise (k=4) 
3. No measure of depression (k=2) 
 
  
 
   
   
    
Effect Sizes Calculated in 
Final Analysis (k=40)a 
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Table and Figure titles and footnotes: 
 
Table 2.  Descriptive characteristics of included studies, subjects and exercise 
interventions by type of cancer (means ± SD, k or % where noted)  
 
NOTE:  Percentages may not sum to 100% due to rounding error.   
CES-D, Center for Epidemiologic Studies Depression scale; POMS, Profile Of Mood 
States; BDI, Beck Depression Inventory; HADS, Hospital Anxiety and Depression Scale; 
SAS, Symptom Assessment Scale. 
k, number of studies included. 
MET, metabolic equivalent, 1MET = 3.5 ml O2∙kg∙min-1. 
a 37 studies provided 40 total effect size estimates 
b 24 studies provided 26 total effect size estimates. 
 
Table 2. Weighted mean effect of exercise modulating depression by type of cancer 
 
NOTE:  Weighted mean effect size values (d+) are negative when the exercise 
intervention was successful in reducing  
depression compare to standard care.   
k, number of studies. 
a37 studies provided 40 total effect size estimates. 
b24 studies provided 26 total effect size estimates. 
 
Table 3.  Multi-moderator intervention characteristics related to depression change for 
all cancer survivors  
NOTE:  Weighted mean effect size values (d+) are negative when the exercise 
intervention reduced depression compared to the control group.  The regression 
equation is -0.2289 – 0.0164(age, yr) + 0.0016(age2, y) + 0.1117(supervised) – 
0.0993(PEDro) – 0.0007(Min week aerobic exercise) – 0.0021(PEDro × Min week 
aerobic exercise), where each continuous variable was zero-centered, and 
categorical variables were contrast coded (+1 vs -1). 
aLevels represent values of interest of each moderator. 
bd+ and their 95% CI estimates statistically adjust for the presence 
of the rest of the moderators in the fixed-effects model, including 
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weekly minutes of exercise  PEDro interaction and their 
independent linear terms, supervision of exercise, quadratic and 
linear trends for age, held constant at their means except for the 
study dimension in question. 
cβ values are standardized. 
dβ for interaction.  Independent β: weekly aerobic volume, β = -0.09; PEDro 
methodological score, β = -0.28. 
eQuadratic trend including linear component. 
 
Figure 1.  Flow diagram of exercise intervention identification and selection 
FOOTNOTE: a Three studies provided two interventions, yielding two effect size 
calculations 
RCT, Randomized controlled trial 
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Systematic search strategy (Supplementary). 
The databases PubMed, PsycINFO, CINAHL Plus, SPORTSdiscus, OregonPDF 
in Health and Performance, and ProQuest Theses and Dissertations were searched 
through Nov 18, 2010. We searched all databases using  a Boolean search strategy [i.e., 
(cancer OR neoplas* OR tumor OR chemo* OR radiat* OR malign* OR carciniom*) AND 
(depress* OR anxiety OR anxious OR worried OR scared OR nervous OR cognitive OR 
biofeedback OR relaxation OR social support OR mind-body) AND (exercise OR 
physical activity OR aerobic OR cardiovascular OR resistance OR strength OR muscular 
OR flexibility OR walking OR program OR interval OR sport OR fitness OR performance 
OR movement OR stretching OR tai chi OR yoga OR dance OR body OR composition)].  
Journals focusing on cancer survivorship (Breast Cancer Research and Treatment, 
Journal of Cancer Survivorship, Oncology Nursing Forum, Journal of Pain and Symptom 
Management and the reference lists of included studies were also searched for 
additional papers.
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Table 4. Clinical, exercise and methodological characteristics of included studies. Supplementary. 
First Author, 
Year, 
Reference 
Clinical Characteristics 
 
Exercise Characteristics  Methodological Characteristics 
Sample Size Type of Cancer 
Freq 
(d∙wk-1) Intensity 
Time (min∙      
session-1) Type 
Duration 
(wk)  
Depression 
Measure PEDro Score 
Mixed Cancer Diagnoses 
Burnham, 
2002,(38) 
I = 12 
C = 6 
Breast 
colon  3 40‒60% HRR 30 
Aerobic; 
treadmill, 
stationary 
cycle, stair 
climber 
10  LASA 7 
Dimeo, 
1999,(39) 
I = 27 
C=32 
Variety; solid 
tumors, 
lymphoma 
 
 7 50% HRR 30 
Aerobic; 
supine biking 
ergometer 
4  POMS 8 
Dodd, 
2010,(40) 
I = 44 
I (Delayed) = 
36 
C =  39 
Breast 
Colorectal 
Ovarian 
 3‒5 60‒80% 
V02peak 
20‒30 
Aerobic; 
walking, 
jogging, 
bicycling 
52  CES-D 8 
Berglund, 
1994,(41) 
I = 98 
C = 101 
Majority 
Breast 
cancer 
 2 n/a 60 n/a 7  HADS 7 
Courneya, 
2003,(42) 
I = 60 
C = 48 
Breast 
Colon 
Ovarian 
Stomach 
Melanoma 
Hodgkin 
Non-
Hodgkin’s 
Brain 
Lung 
 3‒5 65‒75% 
HRmax 
20‒30 
Aerobic; 
swimming, 
cycling 
10  CES-D 8 
Thorsen, 
2005,(43) 
I = 59 
C = 52 
Lymphoma 
Breast 
Gyne-
cologic 
Testicular 
 2 60‒70% 
HRmax 
30 
Aerobic; 
walking, 
cycling, 
jogging 
14  HADS 8 
Breast Cancer 
Daley, 
2007,(16) 
I = 34 
C = 36 Breast  3 
65‒85% 
HRmax 
50 n/a 8  BDI 8 
Courneya, 
2007,(19) 
I (Aer) = 78 
I (RET) = 82 
C = 82 
Breast  3 
60‒70% 
V02max 
2 Sets, 
60‒70% 
15‒45 
Aerobic: cycle 
ergometer, 
treadmill, 
elliptical 
9 strength 
17  CES-D 7 
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First Author, 
Year, 
Reference 
Clinical Characteristics 
 
Exercise Characteristics  Methodological Characteristics 
Sample Size Type of Cancer 
Freq 
(d∙wk-1) Intensity 
Time (min∙      
session-1) Type 
Duration 
(wk)  
Depression 
Measure PEDro Score 
predicted 1-
RM 
exercise 
Culos-Reed, 
2006,(44) 
I = 20 
C = 18 
Majority 
breast  1 n/a 75 Yoga 7  POMS 7 
Rausch, 
2007,(45) 
I = 15 
C = 8 Breast  1 n/a 90 Tai Chi 10  POMS 5 
Ohira, 
2006,(46) 
I = 43 
C = 43 Breast  2 
Progressive 
resistance 60 
Weight 
training 24  CES-D 6 
Perna, 
2010,(47) 
I = 26 
C = 25 Breast  3 
Aerobic: 
50‒85% 
HRmax 
 
 
Weight 
training: 1 set, 
12‒15 reps 
30 
Aerobic; 
treadmill 
walking 
 
Weight 
training; 
weight belts 
12  CES-D 9 
Lee, 2010,(48) I = 16 C = 18 Breast  1 
Light (<40% 
1-RM), elastic 
band, 
medicine ball 
exercise 
40 
Weight 
training of 
shoulder 
muscle 
groups 
8  BDI 5 
Demark-
Wahnefried, 
2008,(49) 
I = 26 
C = 29 Breast  ≥3 
Aerobic: 
walking 
 
Weight 
training: Light 
(<40% 1-RM) 
≥30 
Aerobic 
training; 
walking 
 
Weight 
training: 
elastic band, 
medicine ball 
exercise 
12  HADS 6 
Targ, 
2002,(50) 
I = 74 
C = 60 Breast  1 n/a 90 Yoga 12  POMS 6 
Mutrie, 
2007,(51) 
I =101 
C =102 Breast  3 
50‒75% 
HRmax 
45 
Walking, 
cycling, 
aerobics, 
strength 
exercises 
12  BDI 9 
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First Author, 
Year, 
Reference 
Clinical Characteristics 
 
Exercise Characteristics  Methodological Characteristics 
Sample Size Type of Cancer 
Freq 
(d∙wk-1) Intensity 
Time (min∙      
session-1) Type 
Duration 
(wk)  
Depression 
Measure PEDro Score 
Latka, 
2009,(52) 
I = 37 
C = 38 Breast  5 
60‒80% 
HRmax 
30 Walking 24  CES-D 7 
Patel, 
2004,(53) 
I = 43 
C = 19 Breast  1 n/a 90 Yoga 12  POMS 6 
Vadiraja, 
2009,(54) 
I = 44 
C = 44 Breast  3 n/a 60 Yoga 6  HADS 8 
McClure, 
2010,(55) 
I = 16 
C = 16 Breast  7 
Low‒moderat
e intensity 
17 Arm flexibility exercise 17  BDI 6 
Pinto, 
2003,(56) 
I = 12 
C = 12 Breast  3 
60‒70% 
HRmax 
50 
Treadmill 
walking, arm 
cycling, 
stationary 
cycling, 
rowing 
12  POMS 7 
Mock, 
1997,(57) 
I = 22 
C = 24 Breast  4‒5 Self-paced 20‒30 Walking 6  SAS 7 
Danhauer, 
2009,(58) 
I = 13 
C = 14 Breast  1 n/a 75 Yoga 10  CES-D 6 
Cadmus,  
2009,(59) 
(IMPACT) 
I = 25 
C =25 Breast  5 
60‒80% 
HRmax 
30 Not-specified 24  CES-D 8 
Drouin, 
2005,(60) 
I = 13 
C = 8 Breast  5 
50‒70% 
HRmax 
20‒45 Treadmill walking 7  POMS 7 
Chandwani, 
2010,(61) 
I = 30 
C = 31 Breast  2 n/a 60 Yoga 6  CES-D 6 
Vito, 2007,(62) I =13 C = 12 Breast  2 n/a 90 Yoga 8  POMS 8 
Payne, 
2008,(63) 
I =10 
C = 10 Breast  4 
Moderate 
intensity 20 Walking 12  CES-D 7 
Mock, 
1994,(64) 
I = 9 
C = 9 Breast  ≥3 Self-paced 30 Walking 6  SAS 7 
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First Author, 
Year, 
Reference 
Clinical Characteristics 
 
Exercise Characteristics  Methodological Characteristics 
Sample Size Type of Cancer 
Freq 
(d∙wk-1) Intensity 
Time (min∙      
session-1) Type 
Duration 
(wk)  
Depression 
Measure PEDro Score 
Eyigor, 
2010,(65) 
I = 27 
C = 25 Breast  3 n/a 
20‒30 
 
Pilates 8  BDI 5 
Prostate Cancer 
 
Culos-Reed, 
2010,(18) 
I = 53 
C = 47 Prostate  3‒5 moderate 60 
Walking, 
resistance 
exercise 
16  CES-D 7 
Monga, 
2007,(66) 
I = 11 
C = 10 Prostate  3 65% HRreserve 30 
Treadmill 
walking 8  BDI 7 
Leukemia 
Jarden, 
2009,(68) 
I = 21 
C = 21 Leukemia  1 
50‒75% 
HRmax 
 
1‒2 sets, 
10‒12 reps 
60 
Aerobic: 
Stationary 
cycling 
Resistance: 
Free weights, 
ankle weights 
4‒6  HADS 8 
Chang, 
2008,(69) 
I = 11 
C = 11 Leukemia  5 60‒110 bpm 12 Walking 3  POMS 7 
Lymphoma 
Courneya, 
2009,(17) 
I = 60 
C = 62 Lymphoma  3 
50‒75% 
V02peak 
20‒45 
Recumbent 
cycle 
ergometer 
12  CES-D 8 
Cohen, 
2004,(70) 
I = 20 
C = 19 Lymphoma  1 n/a 60 Yoga 7  CES-D 7 
Colorectal Cancer 
Courneya, 
2003,(67) 
I = 69 
C = 33 Colorectal  3‒5 
65‒75% 
HRmax 
20‒30 Walking 16  CES-D 9 
NOTE: I, Intervention (exercise group); C, control group  
CES-D, Center for Epidemiologic Studies Depression scale; POMS, Profile Of Mood States; BDI, Beck Depression Inventory; HADS, Hospital Anxiety and 
Depression Scale; SAS, Social Anxiety Scale. 
HRmax, maximum heart rate; HRR, heart rate reserve; V02peak, maximal oxygen consumption (ml∙kg∙min-1); bpm, beats per minute; 1-RM, one-repetition maximum 
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Table 5. Bivariate moderator intervention characteristics related to depression reduction for all cancer survivors. Supplementary. 
Study dimension and levela d+ (95% CI)c βd P 
Theory None -0.06 (-0.15, 0.03) 0.26 0.01 
Psychological -0.26 (-0.39, -0.13) 
Supervision of exercise Supervised -0.22 (-0.32, -0.13) 0.37 0.002 
Non-supervised 0.07 (-0.06, 0.21) 
Non-Hispanic white, % 24 -0.34 (-0.52, -0.17) 0.06 0.01 
99 -0.92 (-1.55, -0.29) 
Time since diagnosis, mo 2.8  -0.17 (-0.29, -0.04) 0.35 0.02 
73.0 0.39 (-0.21, 1.00) 
Accumulated weekly volume 
of aerobic exercise, min∙wk-
1  PEDro methodological 
score 
PEDro =   5 ×  90 min∙wk-1 
PEDro =   5 × 150 min∙wk-1 
-0.19 (-0.43, 0.06) 
-0.02 (-0.26, 0.22) 
-0.25 0.03 
PEDro = 10 ×  90 min∙wk-1 
PEDro = 10 × 150 min∙wk-1 
0.05 (-0.24, 0.35) 
-0.35 (-0.61, -0.08) 
Agee, y 39  0.22 (-0.04, 0.47) 0.70 0.001 
 51 -0.19 (-0.27, -0.10)   
 69 0.12 (-0.31, 0.54)   
NOTE:  Weighted mean effect size values (d+) are negative when the exercise 
intervention was successful in reducing depression compared to the control 
group.   
aLevels represent values of interest of each moderator. 
bk, For categorical variables, k denotes number of effect sizes in each group.  For continuous variables, k denotes  
total observations.   
cbivariate d+ (95% CI) were calculated using fixed-effects models. 
dβ values are standardized. 
eQuadratic trend including linear component.
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Table and Figure titles and footnotes (Supplementary): 
Table 4. (Supplementary Material)  Clinical, exercise and methodological 
characteristics of included studies 
NOTE: I, Intervention (exercise group); C, control group  
CES-D, center for epidemiologic studies-depression; HADS, hospital anxiety & 
depression; POMS, profile of mood states; BDI, Beck depression inventory; SAS, 
system assessment scales (100-millimeter axis) 
HRmax, maximum heart rate; HRR, heart rate reserve; V02peak, maximal oxygen 
consumption (ml∙kg∙min-1); bpm, beats per minute; 1-RM, one-repetition 
maximum 
 
Table 5. (Supplementary Material)  Bivariate moderator intervention 
characteristics related to depression reduction for all cancer survivors 
NOTE:  Weighted mean 
effect size values (d+) are 
negative when the 
exercise intervention was 
successful in reducing 
depression compared to 
the control group.   
aLevels represent values of interest of each moderator. 
bk, For categorical variables, k denotes number of effect sizes in each group.  For 
continuous variables, k denotes  
total observations.   
cbivariate d+ (95% CI) were calculated using fixed-effects models. 
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dβ values are standardized. 
eQuadratic trend including linear component. 
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Chapter 5 – Discussion 
 
This thesis includes two studies examining the efficacy of exercise on cancer-
related fatigue (CRF) (1) and depression (2) among adult cancer survivors.  In 
this concluding chapter, the specific aims and hypotheses of these studies along 
with the most relevant findings are reviewed.  Then, the clinical significance and 
the translation of the findings into clinical practice regarding the Ex Rx among 
cancer survivors are discussed.  Lastly, directions for future research and a 
concluding summary are provided. 
Specific Aims & Hypotheses 
Specific Aim 1: To meta-analyze the literature to determine the efficacy of 
exercise on reductions in CRF and depression among cancer survivors.  
Hypothesis 1: Cancer survivors engaging in exercise would demonstrate 
statistically significant reductions in CRF and depression compared to cancer 
survivors receiving standard care.  Cancer survivors engaging in exercise 
experienced statistically significant reductions in CRF and depression when 
compared to cancer survivors receiving standard care.   
Specific Aim 2: To meta-analyze the literature to examine the influence of the 
frequency, intensity, time and type (FITT) components of the Ex Rx on reductions 
in CRF and depression among cancer survivors.  Hypothesis 2: FITT 
components of Ex Rx would modulate the magnitude of the reduction in CRF and 
depression among cancer survivors.  The largest reductions in CRF occurred 
when cancer survivors performed resistance training (i.e., weight training).  CRF 
reductions occurred in a dose response fashion with resistance exercise such 
that as intensity of resistance exercise increased, so did reductions in CRF.  In 
contrast, the largest reductions in depression occurred when cancer survivors 
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performed aerobic exercise.  Depression reduction occurred in dose-response 
fashion with aerobic exercise such that as weekly minutes of aerobic exercise 
increased, so did reductions in depression, a finding observed in higher quality 
trials.  Moreover, larger reductions in depression occurred with supervised 
exercise. 
Specific Aim 3: To meta-analyze the literature to examine the influence of 
patient clinical characteristics on reductions in CRF and depression among 
cancer survivors.  Hypothesis 3: Clinical characteristics of cancer survivors 
would modulate the magnitude of the reduction in CRF and depression resulting 
from exercise.  Subgroup analysis identified breast and prostate cancer survivors 
performing exercise significantly reduced CRF compared to breast and prostate 
cancer survivors receiving standard care.  However, only breast cancer survivors 
performing exercise significantly reduced depression compared to other all types 
of cancer survivors receiving standard care.     
Age moderated the magnitude of the exercise-induced reductions in CRF 
and depression.  Interestingly, contrasting trends emerged with respect to age of 
cancer survivors performing exercise and the magnitude of CRF and depression 
reduction.  Age of cancer survivors performing resistance exercise was positively 
correlated with CRF reduction such that older cancer survivors reduced their 
CRF levels to greater levels than younger cancer survivors.  Whereas cancer 
survivors between the ages of 47–62 yr engaging in aerobic exercise reduced 
their depression levels to greater levels than those <47 or >62 yr.     
Specific Aim 4: To meta-analyze the literature to examine the influence of the 
interactions among FITT components of Ex Rx and patient clinical characteristics 
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on reductions in CRF and depression among cancer survivors.  Hypothesis 4: 
Interactions among FITT components of Ex Rx and patient clinical characteristics 
will modulate the magnitude of reduction in CRF and depression among cancer 
survivors.   This hypothesis was not supported, as we identified no interactions 
among the Ex Rx FITT components and patient clinical characteristics on 
reductions in CRF and depression among cancer survivors.   
Other findings 
Exercise interventions using behavioral change strategies to develop and guide 
cancer survivors through the exercise intervention were more efficacious in 
reducing CRF than exercise interventions not developed or guided by a 
behavioral change model.   
The magnitude of exercise-induced CRF reduction was moderated by the 
methodological quality of the exercise intervention assessed by the PEDro 
methodological score (3).  There was a significant interaction between the PEDro 
methodological score and intensity of resistance exercise prescribed.  Exercise 
interventions of lower methodological quality were efficacious in reducing CRF 
when they prescribed low or moderate intensity resistance exercise.  
Interventions of higher methodological quality were efficacious in reducing CRF 
only when they prescribed moderate-intensity resistance exercise.   
 There was a significant interaction between the PEDro methodological 
score and weekly volume of aerobic exercise.  Exercise interventions of lower 
methodological quality were not efficacious in reducing depression at any weekly 
volume of aerobic exercise, whereas interventions of higher methodological 
quality were efficacious in reducing depression with larger weekly volumes of 
aerobic exercise.  
Physiologic specificity of exercise and modulation of CRF and depression 
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The efficacy of exercise to reduce CRF and depression emerged to be modality 
(or type of exercise) specific.  Resistance training reduced CRF in dose response 
fashion, whereas aerobic exercise reduced depression in dose response fashion.  
Despite the unknown etiology of CRF and depression among cancer survivors, 
several hypotheses are suggested (4, 5).    
CRF associates with variety of physiologic alterations occurring with 
cancer and cancer treatment.  These alterations include decreases in muscle 
mass and muscle strength, and marked increases in pro inflammatory cytokines, 
specifically interleukin-6 (IL-6), IL-1β, and tumor necrosis factor-α (TNF- α) (5).  
Interestingly, resistance exercise elicits increases in muscle mass, muscle 
strength, and a cascade of cytokine responses occurring in dose response 
fashion with exercise intensity among apparently healthy persons (6).  During 
resistance exercise there is an up regulation of anti-inflammatory cytokines, 
specifically IL-6 and IL-10 (6, 7).  This increase in anti-inflammatory cytokines 
results in subsequent down regulation of pro-inflammatory cytokines including 
TNF-α and IL-1β, postulated to result in diminished levels of CRF (5, 7).  
Appropriately, this meta-analysis found resistance training reduced CRF in dose 
response fashion, fully supporting the cytokine dysregulation hypothesis of CRF 
proposed by Al-Majid (5).  Moderate intensity resistance training elicits similar 
cytokine responses in prostate cancer survivors resulting in diminished levels of 
CRF providing additional evidence for this hypothesis in a randomized controlled 
trial (8, 9).  
The specific etiology of depression remains unclear despite 50 yr of 
investigation (10).  Several hypotheses exist including monoamine imbalance, 
hypothalamic pituitary axis dysregulation, and depletion of β-endorphins in the 
brain (10, 11).  Monoamine imbalance is the most widely proposed hypothesis 
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relating to depression.  Monoamines (serotonin, noradrenaline, and dopamine) 
are critical to the efficacy of anti-depressant medication (10).  The function of 
anti-depressants is to retard the rate of monoamine degradation in the body (10).  
This yields higher bioavailability of monoamines, subsequently increasing their 
concentration at synaptic junctions in the brain postulated to result in lower levels 
of depression (10).  The physiologic response to anti-depressant medication is 
similar to that of aerobic exercise (10, 12); increasing the bioavailability of 
monoamines (12).  Acute and chronic aerobic exercise increases monoamine 
concentrations above pre exercise levels, and above those achieved with heavy 
resistance training (13).  This makes aerobic exercise an optimal modality to 
improve monoamine concentration among those with depression.  An acute bout 
of aerobic exercise increases monoamine concentrations from pre exercise 
levels, and chronic aerobic exercise increases monoamine concentration from 
acute exercise levels (12). This monoamine response makes chronic aerobic 
exercise training an efficacious intervention for the management of depression.  
Appropriately, we found aerobic exercise reduced depression in dose response 
fashion; larger volumes of weekly aerobic exercise were more efficacious in 
reducing depression among cancer survivors.  The finding that aerobic exercise 
in dose response was more efficacious than strength training to reduce 
depression supports the monoamine hypothesis proposed by others (10-12).  A 
randomized controlled trial examining aerobic exercise and biomarkers 
associated with depression would provide additional evidence for this hypothesis.   
Clinical significance of the findings and their translation into clinical 
practice  
The current Ex Rx recommendations for cancer survivors suggest a general 
health fitness program focusing on accruing ≥150 min∙wk-1 of aerobic exercise, 
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complimented with two days of resistance exercise, and flexibility training on 
days of non-exercise (14, 15).  Ex Rx guidelines from the ACSM expert 
consensus for cancer survivors are consistent with the recommendations made 
in 2008 for physical activity among healthy Americans (16).   
The current Ex Rx for cancer survivors was not developed and tailored for 
symptom management.  Rather, the generic Ex Rx implements a broad range of 
modalities of light to moderate intensities, likely providing improvements in health 
related components of physical fitness including aerobic capacity, muscular 
strength and endurance, body composition, and flexibility, but providing no 
insight for symptom management. The current Ex Rx recommendations suggest 
a ‘one size fits all’ approach to exercise and symptom management.  The expert 
panel did not provide symptom specific Ex Rx recommendations due to the 
heterogeneity of results in symptom improvements relating to the varying doses 
of exercise prescribed (14).  The lack of evidence regarding symptom outcomes 
was a noted research gap warranting further investigation. The expert panel 
acknowledged, “The existent literature is insufficient to assist fitness 
professionals with the specifics required to ensure that cancer survivors receive 
safe and effective exercise prescriptions” (14).   
This thesis provides support for the dose-response effects of exercise on 
CRF and depression.  More importantly, the findings from this thesis provide 
evidence for hypothesis driven prospective randomized control trials to test the 
dose-response effect of exercise on CRF and depression.  Evidence from future 
randomized trials may confirm the findings of this meta-analysis, suggesting 
refinement of the current Ex Rx based upon magnitude of symptoms experienced 
during and after treatment.   
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The findings of this meta-analysis indicate cancer survivors reporting CRF 
as their chief complaint may reap the largest benefits in CRF reduction by 
engaging in a progressive, supervised, strength training program, complimented 
by aerobic and flexibility exercises.  Strength training should begin with little to no 
weight and progress as appropriate.  Schmitz et al. (17, 18) demonstrated breast 
cancer survivors, with and at-risk for lymphedema, have been able to participate 
in slowly progressive weight training with no maximum intensity restrictions, 
including one repetition maximum testing (1-RM; the maximum amount of weight 
lifted one time).  This trial used weighted Velcro straps or no weight at all for two 
sets of each exercise of 10 repetitions per set.  After being able to perform two 
additional repetitions, for two sets, for two consecutive workouts, the resistance 
increased by the smallest possible increment.  This indicates slowly progressive 
resistance training is safe for breast cancer survivors with and at risk for 
lymphedema, reduces limb swelling, reduces self-reported lymphedema 
symptoms, improves quality of life and body image, and reduces CRF.   
Conversely, the findings of this meta-analysis suggest cancer survivors 
reporting depression as their chief complaint may reap the largest reductions in 
depression by engaging in a structured, supervised, aerobic exercise program 
with the primary goal of achieving large weekly volumes of aerobic exercise, 
complimented by strength and flexibility exercise.  Breast cancer survivors 
accrued ≥150 min∙wk-1 of aerobic treadmill exercise in 12 wk (19), and 225 
min∙wk-1 over 24 wk of training.  Survivors performed 3–5 d∙wk-1 treadmill walking 
for 15–20 min∙d-1 with small weekly increments (i.e., 5–10 min) until 150 or 225 
min∙wk-1 was achieved (20).  These trials provide a model for clinicians to follow 
when prescribing progressive aerobic exercise.  However, accruing ≥150 min∙wk-
1 of aerobic exercise may take longer than 12 wk if pre-diagnosis physical activity 
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levels were low and other comorbidities exist (i.e., obesity).  Jones et al. (21) 
provides a schematic to aid the clinician in identifying the appropriate dose of 
exercise to prescribe by assessing previous and current exercise levels of 
patients.  The schematic provides the appropriate frequency, intensity, time, and 
type of exercise recommended by the current ACSM Ex Rx (4, 11).  Clinicians 
and health fitness professionals should always weigh the risk to benefit ratio 
when prescribing larger or more intense doses of exercise to their patients and 
clients.   
The ACSM expert panel acknowledged the interaction of age with 
exercise training is of special interest as many cancer survivors are older 
because they now living with rather than dying from cancer (14).  We quantified 
the moderating effects of age and the exercise-induced reductions in CRF and 
depression.  Cancer survivors reduced CRF to the greatest magnitude with 
increasing age, whereas cancer survivors age 47–62 yr reduced depression to 
the greatest magnitude (1, 2).  Age modulates CRF and depression differently 
among different types of cancer survivors when performing exercise, suggesting 
age may be a characteristic considered when developing an Ex Rx for symptom 
management.    
Future Research 
This thesis provides continued evidence supporting the efficacy of exercise 
training among cancer survivors.  However, many research questions remain.  
Other clinically relevant side effects of cancer or cancer treatment such as 
anxiety, nausea, and pain and their response to exercise training warrant 
continued investigation.  Existent literature has examined the efficacy of exercise 
training among breast cancer survivors (22).  Future research should investigate 
the safety and efficacy of exercise training on other common forms of cancer 
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including lung, colorectal, prostate, and ovarian cancers.  Furthermore, a majority 
of cancer survivors participating in exercise training studies are Caucasian, non-
Hispanic whites (14).  Noted in the expert consensus statement (14), future 
research needs to examine the efficacy of exercise training among racial and 
ethnic minority groups as well as those of low socioeconomic status.  Future 
trials should examine exercise training among cancer survivors presenting with 
co-morbidities such as cardiac conditions, obesity, metabolic, and bone 
disorders.   
To verify our findings, a large, well-powered, randomized controlled trial 
examining the efficacy of the specific doses and modalities of exercise found to 
be efficacious in reducing CRF and depression among cancer survivors should 
be conducted.  For example, a trial designed to test our findings relating to CRF 
reduction would employ a four arm randomized design with 42 subjects per arm 
(N=168).  This sample would provide 80% power, and two-sided α = 0.05 to 
detect a reduction in CRF.  Participants would be randomized to one of four 
groups: 1) moderate intensity resistance training (60–80% 1-RM; 2 sets; 8–12 
repetitions; 3 d∙wk-1); 2) moderate intensity aerobic exercise (40–60% V02peak, 3 
d∙wk-1); 3) a combination of arms aerobic and strength exercise; or 4) placebo 
wait list control.  This trial would compare different modalities of exercise to 
reduce CRF.  Once the optimal modality of exercise is identified, other program 
variables manipulated in similarly designed trials might include frequency, 
intensity, and time of exercise.    A similar randomized study design could also 
investigate depression as a primary outcome to elucidate efficacious modalities 
of exercise.                 
Conclusion 
 101 
 
This meta-analysis examined the magnitude of the exercise induced reductions 
in CRF and depression among cancer survivors.  Additionally, this thesis 
investigated the Ex Rx and clinical patient characteristics moderating the 
magnitude of the exercise induced responses in CRF and depression among 
cancer survivors.  This thesis provides evidence that resistance training reduces 
CRF, and aerobic training reduces depression among cancer survivors.  Both 
CRF and depression responding to exercise training in dose response fashion.  
This research highlights the importance of the continued development of 
symptom-specific Ex Rx among cancer survivors.  The findings from this thesis 
provide a framework to begin tailoring the FITT components of the Ex Rx for 
symptom specific management of cancer survivors, whereas prior exercise 
interventions have prescribed a ‘one size fits all’ approach to exercise and 
symptom management.  In accordance with current Ex Rx guidelines, all cancer 
survivors should strive to avoid inactivity if at all possible (14).  Cancer survivors 
are encouraged to discuss the safety, feasibility, and efficacy of beginning an 
exercise program with their oncologist or primary care physician.    
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Appendix — Systematic Data Extraction Form 
 
 Exercise and Depression in Cancer Patients and Survivors 
 
 
Study Selection Criteria 
 
Studies must have an intervention intended to affect physical activity behavior in 
individuals who have been diagnosed with cancer (thus studies with no 
manipulation (or studies with a manipulation but in which researchers determined 
the manipulation was ineffective and separated the group for analysis based on 
self-selected exercise), studies with interventions intended to affect another 
behavior in cancer survivors, or interventions intended to affect behavior in 
relatives or friends of cancer survivors are excluded).  
 
1. target adult (over age 18) cancer survivors (excluding 
studies that target pediatric and adolescent cancer 
survivors) 
2. include an appropriate comparison (excluding studies with 
self-selected intervention/ control groups; does not exclude 
pre-test/ post-test design, studies that compare a pre-test 
control group measure to a post-test intervention group 
measure; non-equivalent control group designs or other 
designs that do not use randomization but have 
appropriate comparison data). 
3. include non-independent data (excluding studies that are a 
re-analysis of data in studies already included in the 
analyses, and studies that use the same participants as 
studies already included in the analyses). 
4. include appropriate quantitative dependent variables 
(depression, anxiety, physiological, and exercise 
adherence measures) 
5. provide requisite statistical information to allow for 
calculation of effect size. 
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PHYSICAL ACTIVITY IN CANCER SURVIVORS META-ANALYSIS CODING 
FORM 
24 May 2010 
Note: Throughout, use “.” to indicate missing information. 
 
(V1) _____ Coder (Becky = 1, Blair = 2, Linda = 3, Stacey = 4, Justin = 5, 
Shannon = 6) 
 
Study Information (this page should be coded separately; complete the 
remainder coding pages later, once all information but methods have been 
removed from the folder) 
 
(V2) __ __ __ Study ID #  Full APA citation:  
   
(V3) __ __ __ __ Publication year (consider this missing if unpublished) 
 
(V4) __ __ __ __ Estimated year of data collection (earliest date for data 
collection or manuscript submission/publication; if 
unpublished and date unknown, use year manuscript was 
acquired; for dissertation or thesis, use year)  
 
(V5) _____ Language of publication: 
1=English   3=German    
2=French   4=other, specify: 
_____________________________ 
 
(V6) _____ Source: 
1=journal     2=book     3=thesis/dissertation     4=conference 
paper   5=unpublished document  
6=other published document; specify: 
__________________________ 
 
(V7) _____ Dominant theoretical perspective explicitly stated: 
1=Theory of Reasoned Action/Planned Behavior (Fishbein, 
Ajzen, etc.) 
2=Social cognitive/Self-efficacy/Social learning (Bandura, 
etc.) 
3=Transtheoretical Model (“stages of change”, Prochaska & 
DiClemente) 
4=Health Belief Model (HBM, Rosenstock et al.) 
5=Information Motivation Behavioral Skills Model (IMB, 
Fisher & Fisher) 
6=Protection-Motivation theory (Rogers, etc.) 
7=Self-perception (or –persuasion)/Cognitive dissonance 
(Aronson, Bem, Festinger cited, “hypocrisy” approaches) 
8=Social Action Theory (Ewart)                  9=Social Diffusion 
(Rogers) 
10=Conservation of Resources (Hobfall)  11=Payne 
Theoretical Model 
12=Levine Conservation                            13=Roy Adaptation 
Model 
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14= 5 A’s of Exercise Adoption (ACSM)    15=Other, specify: 
___________________________ 
 
(V8) _____           Type of clinical exercise recommendation 
followed/prescribed: 
 1= National Comprehensive Cancer Network 
Recommendations (NCCN) 
                  2= American College of Sports Medicine Exercise Rx for 
cancer survivors 
                  3= American College of Sports Medicine Exercise Rx for 
(healthy) 
                       4= Australian Association of Exercise and Sport Science 
Exercise (AAESS) 
                       5= Other clinical recommendation; 
specify:____________________ 
 
Sample Characteristics 
 
(V9) Notes on intervention within study relevant to coding (if more than 
one intervention in  study) 
___________________________________________________________
___________ 
 
(V10) _____ Ethnicity reported?    1 = yes; 0 = no  
  
(V11) ____ Proportion White; if whole number available:______ 
(V12) ____ Proportion Black; if whole number: ______ 
(V13) ____ Proportion Latino/Hispanic; if whole number: ______ 
(V14) ____ Proportion Caribbean; if whole number: _____ 
(V15) ____ Proportion Asian; if whole number: ______ 
(V16) ____ Proportion Mixed/other; if whole number: ______ 
 
(V17) _____ Education reported? 1 = yes; 0 = no 
 
(V18) _____ Proportion high school only: _____ 
 
(V19) _____ Proportion college only: _____ 
 
(V20) _____ Proportion graduate school:_______ 
 
(V21) ___ SES 
 0 = Not given 
 1= Low 
 2 = Middle 
 3 = High 
  
(V22) _____ Region of sample 
1=American city: __________________ 
2=other U.S. general region (city not specified):  
__________________ 
3=Canada  (city: _______________________) 
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4=Europe (city: _______________________) 
5=South or Central America, Mexico, Caribbean (city: 
_______________________) 
6=Africa  (city: _______________________) 
7=Asia (city: _______________________) 
8=Australia (city: _______________________) 
 
(V23) _____ City size 
 0=not given 
 1=rural (< 10 thousand people) 
 2=small (10 – 100 thousand people) 
 3=medium (100 thousand – 1 million people) 
 4=large (more than 1 million people) 
(V24) ___ Zip Code (US Only) _______ 
(V25) ___ City: ______________________  
 
(V26) _____ Average age of sample ___________ 
(V27) _____ SD for age _____________________ 
 
(V28) _____ Population 
1=school or college 
2=community, not currently institutionalized; specify source (e.g., 
cancer clinic including University cancer treatment 
facilities)_____________________________________________
___________ 
3=institutionalized; specify source (e.g., inpatient cancer 
treatment center; currently hospitalized): 
______________________________________________
__________ 
0=not given 
 
Risk Characteristics 
 
(V29) _____ Proportion of sample overweight; if whole number: 
_______ 
 
(V30) _____  Average minutes of exercise at baseline: ______ 
 
(V31) ____ Type of cancer: 
 1=breast 
 2=prostate 
 3=head and neck 
 4=colorectal 
 5=skin 
 6=leukemia 
 7=myeloma 
 8=lymphoma 
 9=gastrointestinal 
 10=lung 
 11=ovarian 
 12=pancreatic 
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 13=bladder 
 14=endometrial 
 15=kidney/renal 
 16=appendix 
 17=cervical 
 18=testicular 
 19-brain 
 0=combination (list numbers): _______ 
 
(V32) _____ Average Length since cancer diagnosis (in months):  
______ 
(V33) _____ Proportion of participants in remission 
  
(V34) _____  Treatment (if more than one, indicate percentages) 
0=none currently 
1=chemotherapy 
2=radiation 
3=surgery 
4=transplant 
5=hormones 
other (specify): _______ 
(V35) _____ Proportion of participants under chemotherapy in the 
past 
(V36) _____ Proportion of participants currently under chemotherapy  
(V37) _____ Proportion of participants under radiation in the past 
(V38) _____ Proportion of participants currently under chemotherapy 
 
(V39) _____ Average length under treatment  
(V40) _____ Average length under non treatment 
(V41) _____ Proportion of the sample under drug treatment (specify: 
___________________) 
(V42) _____ Proportion of the sample with other diseases (specify: 
___________________) 
(V43) _____ Proportion of overweight sample 
(V44) _____ Proportion of the sample under drug treatment (specify: 
___________________) 
(V45) _____ Proportion of smokers on the sample 
 
 
Design & Measurement 
 
(V46) _____ Recruitment method 
1=self-selected from community (via flyers, community 
centers, etc.) 
2=recruited through clinical contact (cancer clinic, etc.) 
3=recruited through hospital 
4=other (specify): __________ 
0=not given 
 
(V47) _____ Type of control group used 
 True control groups 
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1=random assignment of individuals to conditions 
2=matching individuals on some variable (specify: 
__________________________), then random 
assignment 
3=random assignment of some groups of individuals (e.g., 
classrooms) 
   Nonequivalent control groups (comparison group) 
4=tried to ensure some comparability of the nonequivalent control group 
by: (e.g., comparing on some var): 
________________________________________________________
______________ 
5=the nonequivalence of comparison group was not 
addressed 
 
(V48) _____  Number of follow-ups: _______ 
(V49) _____  Interval of follow-ups: _______ 
(V50) _____  Scale used to measure depression: 
___________________________________________ 
(V51) _____  Scale used to measure anxiety: 
_______________________________________________ 
 
  Control for social-desirability bias in self-report  
(V52) _____  Anonymity attempted (1 if unclear)      
      1=no    2=yes    0=no measures self-report 
   
(V53) _____  Low reactivity of measure completion (1 if unclear)      
1=no; intervention and measurement staff were the same 
&/or face-to-face interviews used 
2=yes; used different personnel for intervention and 
measurement, and measurement technique not highly 
reactive (written questionnaires used rather than oral 
responses) 
0=no self report 
 
Experimental (Intervention) Condition Details 
 
(V54) _____  Length of intervention in weeks: ________ 
(V55) _____ Aerobic/ Cardiovascular Activities (in METS as defined in 
excel file) 
(V56) _____ Resistance/ Strength Activities (in METS as defined in 
excel file)   
(V57) _____ Flexibility 
0=no    
1=yes 
(V58) _____  Description of exercise based on report (take description 
of exercise):    _________________________________ 
(V59)  ____ Structure of intervention 
 1=incentive (e.g., payment based on sessions attended) 
 2=supervised (group exercise sessions provided) 
  3=unsupervised (education, etc. provided, but participants 
expected to exercise on own) 
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  4=lifestyle activity 
(V60)  ____  Intervention for weight loss or weight gain: 
 1=loss 
  2=gain 
  3=neither 
(V61)  _____ Type of intervention 
0=exercise only 
1=exercise and diet 
2=exercise and diet other (specify): _________ 
     3=exercise and other (specify): _______ 
 
(V62) _____  Level of intervention used in the study 
1=primarily one-on-one (e.g., individual counseling sessions; 
individuals each exposed to persuasive messages alone 
or in a group) 
2=small group processes (interaction between leader and 
group, and group members) 
3= small group processes (interaction among the group 
members, there is not leader) 
4=single community (e.g., street studies with mix of media 
and face-to-face interventions) 
5=multiple communities (e.g., mix of media and face-to-face 
interventions) 
 
(V63) _____  Number of experimental conditions for which effect sizes 
will each be calculate (if some experimental conditions in 
the study are omitted here, explain why they are excluded: 
_______________________________________________) 
 
(V64) _____  Number of DVs for which effect sizes will be calculated 
for each experimental condition 
 
 
Experimental condition ______________________________ (give label for 
condition, e.g., that used in the article) 
 
Intervention Details   for INTERVENTION GROUP:  (use label from study): 
______________________________ 
(V65) _____ Number of sessions  
(V66) _____ Number of minutes for each session; if varies, report 
average; specify each: ___________________ 
(V67) _____ Average size of participant group for a session 
(V68) _____ Number of facilitators/experimenters per group   
 
(V69) _____ Training of session leaders or speakers  
  1=professionals—formal matriculation, licensing, or degree 
  2=paraprofessionals 
  3=peers 
  0=not given 
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(V70) _____ Content of the intervention (NOT the measures) matched to 
sample  
0=no mention of elicitation research, focus groups to 
determine relevant issues for this population 
1=mention of informal assessment of determining content 
through some kind of elicitation research, or pilot testing of 
content 
2=systematic formal assessment of appropriate content—
e.g., focus groups with content analyzed, or previous 
paper analyzing results of elicitation research 
3=not reported 
 
(V71) _____ Number of participants who began study (in 
experimental group) 
(V72) _____ Final N in experimental group (after attrition—use largest 
available) 
(V73) _____ Number of participants who did not complete the study 
due to cancer-related mortality 
(V74) _____ Number of participants who did not complete the study 
due to cancer-related illness/ complications 
(V75) _____ Proportion of women in sample; if whole number 
available: ______  
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CONTROL CONDITIONS: USE THE FOLLOWING SCHEME: 
 
   Codes for control conditions 
 
1=wait-list/no treatment/no contact control group 
2=exercise education only  
3=irrelevant content (+/- education), matched for time/contact to 
experimental condition 
4=brief form of experimental condition describe: ___________________ 
5=other kind of comparison condition;  specify: 
______________________ 
 
 
 
(V76) _____  Number of control/comparison groups in the study (do not 
count any that are reasonably considered experimental 
conditions); describe each: 
 
 
 
 
 
(V77) _____ Number of participants n control group  
(V78) _____ Final Control N (after attrition—use largest available at 
posttest) 
(V79) _____ Number of participants who did not complete the study 
due to cancer-related mortality 
(V80) _____ Number of participants who did not complete the study 
due to cancer-related illness/  
 complications 
(V81) _.___ Proportion of women in sample; if whole number 
available: ______  
(V82) _.___ Proportion men in sample; if whole number: _______ 
 
 
Criteria for selecting control groups for effect size calculations: 
If control condition type 1 is available, use it; otherwise use group 2 to 
calculate effect sizes; all others should be considered as experimental 
conditions. If neither control type 1 or 2 is available, use the control condition 
corresponding to the lowest numerical value above (e.g., use 3 if available, 
otherwise 4, otherwise 5). 
 
 
(V83) _____ Using the key above, list the code for the control group 
used in effect sizes 
 
Content of Control Group (in calculating time, do not include 
measurement completion time when possible) 
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(V84) _____ Number of sessions in control group 
(V85) _____ Number of minutes for each session; if varies, report 
average (estimate if necessary); specify each: 
__________________________________ 
(V86) _____ Average size of participant group for a session (blank if no 
contact/wait list) 
(V87) _____ Total minutes of exercise information (estimate if 
necessary) 
(V88) _____ Total minutes of non-exercise education presented (estimated) 
 
1. Eligibility criteria were specified 
1 = Yes 
0 = No   
2. Subjects were randomly allocated to groups (in a crossover study, 
subjects  
were randomly allocated an order in which treatments were received)  
1 = Yes 
0 = No  
3. Allocation was concealed  
1 = Yes 
0 = No  
4. The groups were similar at baseline regarding the most important 
prognostic  
indicators 
1 = Yes 
0 = No  
5. There was blinding of all subjects  
1 = Yes 
0 = No  
6. There was blinding of all therapists who administered the therapy  
1 = Yes 
0 = No  
7. There was blinding of all assessors who measured at least one key 
outcome 
1 = Yes 
0 = No  
8. Measures of at least one key outcome were obtained from more than 
85%  
of the subjects initially allocated to groups  
1 = Yes 
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0 = No  
9. All subjects for whom outcome measures were available received the  
treatment or control condition as allocated or, where this was not the 
case,  
data for at least one key outcome was analysed by “intention to treat” 
1 = Yes 
0 = No  
10. The results of between-group statistical comparisons are reported for at 
least one 
key outcome  
1 = Yes 
0 = No  
11. The study provides both point measures and measures of variability for 
at  
 least one key outcome 
1 = Yes 
0=No 
 
